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Abstract 
Vibrio cholerae O1 and enterotoxigenic Escherichia coli (ETEC) together account for the 
majority of bacterial causes of acute dehydrating diarrhea in children in Bangladesh. Vaccines 
should be considered as an important public health tool for prevention of these diarrheal diseases. 
However, a limitation for the use of vaccines in developing countries is that the efficacy and 
immunogenicity of vaccines, especially oral enteric vaccines, are lower in these countries than in 
the industrialized world. The main objectives of the thesis were to study the safety and 
immunogenicity of oral cholera toxin B subunit (CTB) containing inactivated whole cell ETEC 
and cholera vaccines in young children in a developing country and to identify possible immune 
modulating factors, e.g. vaccine dose, different buffer formulations, effects of breast milk 
withholding and zinc supplementation. 
 
For determining optimal doses of the ETEC vaccine, we immunized 6 months to 12 year old 
children with full, half and quarter doses of the ETEC vaccine. Safety and immunogenicity of 
different vaccine doses were compared. All doses of the ETEC vaccine were found to be equally 
immunogenic in the older children. However, a quarter dose, although giving somewhat lower 
antibacterial responses than a full dose, was required for children 6-18 months to avoid 
reactogenicity.  
 
For determining the safety and immunogenicity of the cholera vaccine in young children and the 
effect of different interventions to try to enhance immune responses, children 6-18 months of age 
were given two doses of the vaccine according to the standard protocol or with different 
modifications. In addition to analyzing antibacterial and antitoxic B-cell responses, T-cell 
responses were determined using a new flowcytometric technique, FASCIA. The vaccine was 
found to be safe and to induce both antibody and Th1 type T-cell responses. Vibriocidal antibody 
responses were improved by temporarily withholding breast-feeding for three hours before 
immunization as well as by giving 20 mg of zinc from 3 weeks prior to and one week after the 
second dose of vaccine. Zinc supplementation also enhanced IFN- responses to CTB. 
 
Further objectives of this thesis were to analyze the immune responses to one of the most 
prevalent ETEC colonization factors (CFs), i.e. CS6, in patients infected with CS6-positive ETEC 
and to evaluate if there is an association between expression of certain Lewis blood group 
antigens of the host and infection by ETEC expressing different CFs. Natural infection with CS6 
ETEC was found to induce robust systemic and mucosal immune responses in 70-90% of adults 
and children with diarrhea caused by CS6 positive ETEC strains,  suggesting that CS6 could be 
an important immunogenic component of a new ETEC vaccine. We could also show that 
individuals with Le (a+b-) blood group had increased susceptibility to infection with ETEC 
expressing CFA/I group fimbriae.  
 
The results of these studies give important background information regarding the possibility of 
inducing effective immune responses to oral inactivated enteric vaccines in young children in 
developing countries.  
 
Keywords: Vibrio cholerae, ETEC, oral vaccine, CS6, CFA/I, Lewis blood group, zinc, breast 
feeding, T cell, B cell 
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Ag Antigen  MSHA Mannose-sensitive haemagglutinin 
ALS Antibody in lymphocyte supernatants  NCHS National center for health statistics 
ASC Antibody secreting cell  n.t. Not tested 
BC Birth cohort  PBMC Peripheral blood mononuclear cell 
CT Cholera toxin  PHA Phytohaemgglutinin 
CTB Cholera toxin B subunit  RBC Red blood cell 
CF Colonization factor  rCTB Recombinant CTB 
CFA Colonization factor antigen  RF Responder frequency 
CFU Colony forming unit  SD Standard deviation 
chMP Vibrio cholerae O1 membrane protein  SEM Standard error of mean 
cAMP Cyclic adenosine monophosphate  sIgA Secretory IgA  
cGMP Cyclic guanosine monophosphate  ST Heat stable toxin 
CS Coli surface  TCP Toxin-coregulated pilus 
ELISA Enzyme linked immunosorbent assay  Th T helper 
ELISPOT Enzyme linked immunospot  TNF Tumor necrosis factor 
ETEC Enterotoxigenic Escherichia coli  Vacc Vaccine 
FACS Fluorescent activated cell sorter  VCO1 Vibrio cholerae O1 
FASCIA Flow cytometric assay of specific 
cell-mediated immune response in 
activated whole blood 
 WC 
Zn 
ZnDef 
Whole cell 
Zinc 
Zinc deficient 
Fuc  L-Fucose   ZnSuf  Zinc sufficient 
FUT  Fucosyl transferase  ZnVacc Zinc plus vaccine 
Gal D-Galactose    
GlcNAc  N-acetylglucosamine    
GM1 Ganglioside monosialic acid 1    
GMT Geometric mean titer    
HIV Human immunodeficiency virus    
ICDDR,B International Centre for Diarrhoeal 
Disease Research, Bangladesh 
   
IFN Interferon    
Ig Immunoglobulin    
IL Interleukin    
LPS Lipopolysaccharide    
LT Heat labile toxin    
Le Lewis    
mCTB Mutant/modified CTB    
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INTRODUCTION 
 
The noninvasive diarrheal pathogens Vibrio cholerae O1 and enterotoxigenic Escherichia 
coli (ETEC) together account for the majority of bacterial causes of acute diarrhea in 
hospitalized and community based settings in children in Bangladesh. Overall, these two 
pathogens cause about 35% of the hospitalization due to diarrhea in children up to 5 years 
of age.  The two pathogens share many clinical and epidemiological features. Peak rises 
in rates are seen twice a year, once in the spring and then again in the post-monsoon 
season with additional peaks during natural disasters (Figure 1).  
 
 
 
 
 
 
 
 
 
Figure 1. Isolation of enterotoxigenic E. coli (ETEC) and V. cholerae O1 (VCO1) from 
diarrheal stools of under-5 children obtained from the 2% systematic sampling at 
International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) Dhaka 
Hospital during the period of 2002-2007. 
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Both ETEC and V. cholerae O1 cause dehydrating diseases in adults and children. 
Cholera can cause severe disease in both children and adults while ETEC diarrhea is 
often more severe in adults (128). Both pathogens induce mucosal and systemic antitoxic 
as well as antibacterial immune responses in patients (124, 181) and effective vaccines 
should stimulate such responses. Immunity in these diseases is dependent on the 
stimulation of the mucosal immune system and generation of secretory IgA (sIgA) 
antibodies in the gut associated lymphoid tissue (72, 96), and antibodies present on the 
mucosal surfaces of the gut as well as memory B cells can protect against subsequent 
disease. 
 
The control of diarrheal diseases has made progress over the past decade. However, even 
now about 2.0 million children die each year from diarrheal diseases that are potentially 
vaccine preventable. If effective vaccines could be made available against V. cholerae 
and ETEC, a large proportion of the diarrheal disease burden would be decreased. 
Additionally, the prevention of disease in children during the first 5 years of life could 
also reduce mortality. The World Health Organization and other international agencies 
have given high priority to the control of cholera and ETEC diarrhea through vaccination, 
since effective vaccines appear to be the most appropriate preventive interventions for the 
developing world.  
 
The development of candidate vaccines for children in developing countries is however 
associated with substantial problems, since these children often fail to mount strong 
immune responses to different vaccines. Effective vaccination strategies require to be 
optimized to overcome the hyporesponsiveness and studies to determine the role of 
undernutrition, including micronutrient deficiency, environmental factors, breast feeding 
patterns and the influence of genetic factors would be important to improve 
immunogenicity as well as the effect of different doses of vaccine and the role of 
adjuvants.  
 
A whole cell killed cholera vaccine containing B subunit of cholera toxin (CTB) is 
licensed in many countries of the world, while an oral inactivated  ETEC vaccine with a 
similar formulation as that of the cholera vaccine has been tested in Phase III studies in 
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large groups of both adults and children (139, 145). Both of these vaccines have proved 
efficacious when tested in adults but particularly the ETEC vaccine has been found to be 
less effective in children in resource poor settings, e.g. in Egypt and Bangladesh (116, 
139, 145). To make vaccines effective for infants and young children in such settings, 
there is a need for improved composition of the candidate vaccines and/or modified 
immunization regimens. The issues relevant to the composition of the candidate vaccines 
need attention, but equally important are other factors that may affect vaccine responses, 
e.g. the nutritional status of the vaccinees, environmental factors and genetic diversity. 
 
CHOLERA 
Cholera Epidemiology 
V. cholerae O1 is a major diarrheal pathogen (35) causing millions of cases and at least 
200,000 deaths in adults and children each year (35, 91, 93). It is assumed that there are 
at least 300,000 severe cases and 1.2 million infections in people in Bangladesh alone. 
The rate of cholera varies from around 1 to 8 per 1000 people and the highest attack rate 
is in children 2 to 9-year of age (124). Cholera is now also being documented in very 
young children (35, 148).  After colonizing the proximal small intestine, the bacteria 
produce cholera toxin (CT), the major virulence factor for all toxigenic strains of V. 
cholerae. CT is a heterodimeric exotoxin which consists of a single, enzymatically active 
A subunit non-covalently associated with five identically-sized B subunits responsible for 
binding to ganglioside monosialic acid 1 (GM1) receptors on epithelial cells (50). CT 
activates adenylate cyclase in the mucosal epithelium causing a profuse secretory 
diarrhea, which is a characteristic feature of cholera disease. 
 
Natural protection against cholera 
Studies to-date in patients with  cholera suggest that different components of the immune 
system, both humoral and cell mediated, innate as well as adaptive, are activated in 
response to natural infection (8, 119, 125). The best studied responses are the humoral 
immune responses and both mucosal and systemic antibody responses have been found to 
be related to protection (70, 155, 158). The serological responses such as the complement 
mediated vibriocidal antibody response, antibody responses to lipopolysaccharide (LPS) 
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and CT as well as to protein antigens have been found to be significantly increased in 
response to clinical cholera (26, 70, 158).  The antibacterial responses include, in addition 
to LPS, responses to the toxin-coregulated pilus (TCP), which is a colonization factor and 
potentially protective antigen (9, 165, 177), as well as to the mannose sensitive 
haemagglutinin (MSHA), a type IV pilus antigen (76) which  is also immunogenic and 
gives rise to antibody secreting cell (ASC) responses and fecal as well as plasma 
antibodies in patients (123) (Table 1). SIgA antibodies to the major protective antigens 
have been detected in mucosal secretions of patients, e.g. in intestinal lavages, feces as 
well as in breast milk and saliva specimens. Of these, fecal extracts have been found 
useful due to the ease of collection, and relatively satisfactory mucosal responses have 
been estimated in patients and vaccinees using these samples (70, 72, 147, 155). There is 
however a need for more sensitive analytical methods and appropriate clinical specimens 
to better gauge the mucosal response.  
 
Table 1. Immune responses to specific protective antigens of Vibrio cholerae O1 in 
response to natural infection.   
 
Antibody responses in  
Serum Stool Saliva 
CTB +++ ++ + 
LPS + + + 
TCP + + n.t.1 
MSHA ++ + n.t. 
Vibriocidal  +++ - - 
1n.t. stands for ‘not tested’ 
Cholera vaccines 
Vaccines which reduce the rates of cholera will provide an overall health benefit for 
children and adults who are at risk of disease. There are currently three oral cholera 
vaccines that are licensed in different parts of the world. The first, Dukoral, has been 
developed at the University of Gothenburg and is commercially produced by SBL 
Vaccin, Stockholm, Sweden. This vaccine contains recombinant CTB plus heat and 
  ‐ 13 ‐
formalin killed V. cholerae organisms thus stimulating both anti-bacterial and anti-toxic 
immunity (Box 1).  
 
Box 1. Composition of the cholera vaccine used in the studies.                     
 
 
 
 
 
 
 
 
1WC stands for whole cell  
 
This cholera vaccine should be given as two doses to individuals 6 years, and as three 
doses to children aged 2-6 year, at 1–6 week intervals between doses, with a buffer to 
protect CTB against stomach acidity.  Before being licensed, this vaccine was extensively 
tested in both adults and children in large field trials in cholera endemic areas (24, 28, 85, 
94) and it is now licensed in over 50 countries of the world, including Sweden and 
Bangladesh. The vaccine provided a very high degree of short term protection in all age-
groups, 85-90% (26), but a more lasting protection in adults (~60% during 3 years) than 
in children in a field trial carried out in Matlab in Bangladesh (26). Subsequent analyses 
of data from the field trial in Bangladesh showed that a greater than 90% reduction in 
cholera disease burden could  be achieved by this vaccine through herd protection, even 
when the level of coverage was only moderate (~50% - 60%) (5, 6, 91). The vaccine 
gives rise to intestinal sIgA responses directed against CTB as well as against V. cholerae  
LPS, which are thought to synergistically contribute to the protection afforded by the 
vaccine (118, 125, 147, 155, 156) (Table 1). The vaccine enhances serum vibriocidal 
antibody responses, which is known to be the best available indirect correlate of 
WC-CTB-Cholera Vaccine (Dukoral)1 
Consists of the following V. cholerae O1 
components  (1x1011 bacteria/dose):  
   
   Formalin-killed El Tor Inaba (strain Phil 6973) 
   Heat-killed Classical Inaba (strain Cairo 48) 
   Heat-killed Classical Ogawa (strain Cairo 50) 
   Formalin-killed Classical Ogawa (strain Cairo 50) 
 
   plus 1 mg of  rCTB  
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protection after oral immunization or infection (105, 106); it also induces systemic 
antibody responses against CTB and LPS (71, 125, 155). However, less is known about 
the T-cell responses induced after immunization with this cholera vaccine. In mice, T-cell 
responses to CT are strictly dependent on the presence of CD4+ T cells (39, 97, 98). 
Studies also suggest that humans mount CTB-specific T-cell responses to the oral cholera 
vaccine (21, 87).  
 
The cholera vaccine has mostly been tested in adults and children >2 years, but the 
disease is also seen in infants and under 2 year old children (148, 153). Therefore, it is 
important to test the vaccine in younger children down to 6 months of age where the 
disease is prevalent, especially when maternal antibody protection wanes and weaning 
from breast feeding is generally initiated (53, 54, 104). 
 
The second licensed oral cholera vaccine, CVD 103HgR or Orochol that was 
previously produced by Berna/Crucell, is a single-dose, live attenuated vaccine. It was 
derived from the classical Inaba 569B strain with 94% deletion of the enzymatically 
active A-subunit of the cholera toxin leaving only the immunologically active B-subunit 
(29). This vaccine was shown to be safe and immunogenic in various trials in North 
America (81), Switzerland (30), Peru (55), Indonesia (149, 152) and in HIV seropositive 
individuals in Mali (110) and was also protective in challenge studies in the US (164). 
However, a large field trial with more than 67,000 subjects in Indonesia failed to show 
protective efficacy (133). Production of this vaccine was stopped several years ago (93). 
 
Another killed oral whole cell cholera vaccine is available which is produced in Vietnam 
by the local manufacturer Vabiotech following technology transfer from Sweden. This 
vaccine consists of killed V. cholerae O1/O139 whole cells (WC) and has been shown to 
be safe and immunogenic in subjects aged 1 year and older (171) and to have 50% long 
term effectiveness in Vietnam (168). This vaccine was initially only licensed in Vietnam 
but has very recently also been licensed in India. In order to expand the use of this 
vaccine globally, the vaccine has been reformulated, and is currently under trial in 
Kolkata, India (99); production is now being conducted by a WHO-prequalified vaccine 
manufacturer in India (Shanta Biotech, India). 
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Several other live and killed candidate vaccines have been developed or are currently in 
development. Among them, Peru-15 (80, 120, 121, 166), V. cholerae 638 (48), CVD 111 
(163, 167) and a combined B-subunit bivalent O1/O139 vaccine (70) should be 
mentioned.  
 
ETEC 
ETEC epidemiology 
It has been estimated that diarrhea due to ETEC alone causes 650 million episodes of 
diarrhea and over 380,000 deaths annually in children less than five years of age (13, 15), 
but ETEC diarrhea are also frequent in adults in endemic countries (184) as well as in 
travelers to these regions (14, 73). The clinical symptoms of the disease include watery 
diarrhea often accompanied with abdominal cramps, malaise, and low grade fever. The 
disease may last from 3-7 days and symptoms range from mild diarrhea to dehydrating 
cholera like disease, which is seen in about 5% of cases and mostly in adults (128).  
 
Pathogenesis and mechanisms of immunity against ETEC diarrhea 
The pathogenicity of ETEC is due to the ability of the bacteria to colonize the small 
intestine and  produce one or both of two types of toxins, the heat-stable (ST) and/or 
heat-labile (LT) enterotoxin (6, 13, 128, 141, 160). The bacteria also possess a variety of 
surface located adhesins, termed colonization factors (CFs) that attach them to intestinal 
mucosal receptors (41, 45, 172). The LT toxin has a similar structure as CT, whereas ST 
is a small non-immunogenic protein. After colonization, toxin secretion increases 
intracellular cAMP or cGMP which leads to hypersecretion of water and electrolytes into 
the bowel lumen in a similar way as CT.  
 
Natural ETEC infections are protective with an age related decrease in infection starting 
from 5 years of age (10, 92). Antibodies that can be induced locally in the gut are 
believed to be protective and antibodies directed against the CFs have been shown to 
cooperate synergistically with antibodies to LT in providing protection (3, 160). Studies 
in animal models and human volunteer studies also suggest that ETEC infections can 
protect against reinfections (86, 127, 131, 162).  
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ETEC express a large number of CFs, of which the most common and best characterized 
ones are CFA/I, and the coli surface (CS) antigens CS1, CS2, and CS3 (collectively 
designated as CFA/II), CS4, CS5, and CS6 (previously collectively designated as 
CFA/IV) (46). There are also different related fimbriae, e.g. within the CFA/I and CS5 
families (7); within each of these families there are cross-reactive epitopes that have been 
considered as protective antigens for candidate vaccine development (7, 114, 136). 
 
The CS6 colonization factor of ETEC is seen increasingly in clinical ETEC isolates (138, 
146, 187). Most CS6-expressing ETEC strains express ST (LT/ST or only ST). CS6 is a 
non-fimbrial polymeric protein (3, 128, 131, 135, 189) and has been shown to promote 
binding of ETEC to rabbit and human enterocytes but not to cultured intestinal cells and 
other human-derived tissue (61, 62). Very recently, CS6 was shown to bind strongly to 
sulfatide or sulfatide structures that are present in high concentration in rabbit or human 
enterocytes (66). The CS6  antigen is present either alone or in association with CS4 or 
CS5 on ETEC strains producing either ST or both enterotoxin types (46, 128, 187). Little 
is known about the capacity of CS6 to induce immune responses in humans compared to 
the other ETEC CFs (63) and it is not clear if anti-CS6 responses may protect against 
reinfection, since detailed studies of immune response to CS6 have not been carried out 
in ETEC patients (63). Such information is important for understanding the requirements 
for and the design of an effective vaccine to protect against CS6-expressing ETEC.   
 
ETEC vaccines 
Efforts have recently been intensified to develop vaccines for protection against ETEC 
diarrhea (161, 180). Since both anti-CF and anti-toxic immunity are essential for 
protection, both types of antigens have been targeted for inclusion in candidate vaccines. 
Based on the epidemiological and clinical data on ETEC, it is believed that a vaccine 
suitable for all settings and regions will be one with a multivalent composition containing 
the major CF antigens as well as an LT toxoid. The ST toxin, although being a potent 
virulence factor, has not yet been included in vaccine formulations since it is not 
immunogenic in its native form and efforts to prepare immunogenic conjugates have 
failed so far (161).  A vaccine containing the most prevalent CFs and  an LT toxoid has 
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the potential to provide protection against over 80% ETEC strains all over the world 
(157, 160). 
 
Box 2. Composition of the ETEC vaccine used in the studies.  
                  
CF-CTB-ETEC Vaccine 
Consists of 5 formalin-inactivated strains of 
ETEC (1x1011 bacteria /dose) expressing:  
                  
                 CFA/I 
                 CS1 
                 CS2 
                 CS3 
                 CS4 
                 CS5   
          
                 plus 1 mg of  rCTB  
 
 
Several groups have conducted work to construct inactivated and live vaccine candidates 
to prevent ETEC diarrhea (161, 184). For one vaccine, the oral CF-CTB-ETEC vaccine, 
the same concept as used for development of Dukoral has been applied. This ETEC 
vaccine is composed of inactivated ETEC strains expressing CFA/I and five of the most 
prevalent CFs (CS1, CS2, CS3, CS4, and CS5) as well as recombinantly produced CTB 
(rCTB), which is antigenically related to LT (Box 2). This vaccine has been tested 
extensively in ETEC endemic countries like Egypt and Bangladesh as well as in Swedish 
volunteers and travelers from the US to Guatemala and Mexico over the last 15 years (2, 
57, 69, 117, 129, 139, 144, 145, 161, 179). The vaccine has protected travelers from more 
severe ETEC  disease, whereas it did not afford any significant protection in children in 
Egypt (161, 180, 184).  In Bangladesh,  phase I/II studies showed that the vaccine was 
safe and immunogenic in adults as well as in children down to 18 months of age (117, 
129). Since ETEC is most prevalent in infants and young children in developing 
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countries, causing not only mortality and morbidity but also growth retardation and 
growth faltering, the vaccine has been tested in children with decreasing age, who are at 
risk developing of ETEC diarrhea (15, 16, 59).  
 
Based on the high prevalence of CS6-positive ETEC, this CF is now considered an 
important antigen to incorporate in an ETEC vaccine. Efforts have been made to 
administer CS6 by different immunization routes, including the oral (42, 79, 180), 
transcutaneous (56, 189), and intranasal routes in mice (19, 34). Strategies for designing 
CS6 containing ETEC vaccines for use in humans has included the development of an 
oral inactivated vaccine (161), oral live attenuated strains expressing CS6 (172, 173) or 
recombinant CS6 antigen. Efforts to express CS6 in high amounts on ETEC strains (170) 
is one strategy to optimally deliver the antigen in oral or live vaccine preparations.  
Another CF antigen, CS7, may also be considered for incorporation in an effective ETEC 
vaccine, since recent data suggest that it is becoming the most prevalent ETEC in some 
regions (59) and particularly in children (122). 
 
FACTORS INFLUENCING THE IMMUNE RESPONSES TO ORAL 
VACCINES 
Hyporesponsiveness of vaccines in children in developing countries 
The efficacy and immunogenicity of oral mucosal vaccines in children are generally 
lower in children in developing than in developed countries (138). This has been found to 
be the case for cholera (52, 133), rotavirus (89, 90, 132), ETEC (160, 161, 180),  typhoid 
vaccines (150) and also for oral polio vaccine (75). There are a number of factors that 
may contribute to such decreased vaccine “take rates” in children in these settings. These 
factors may include frequent breast feeding behavior, poor nutritional status, maternal 
malnutrition and low birth weight of the child. It is believed that maternal trans-placental 
antibodies and breast milk antibodies as well as non-immunoglobulin factors in breast 
milk might limit stimulation by the vaccine antigens in the gut and adversely influence 
the immune responses (138). These effects may be more pronounced in developing 
countries where breast feeding is more frequent during the first 24 months of life and 
breast milk may contain higher levels of antibodies against specific pathogens compared 
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to in developed countries. E.g. breast feeding has  been shown to interfere with the serum 
immune responses to oral rotavirus vaccine, although this effect could be overcome by 
administering three rather than one dose of the vaccine (132).    
 
The number of doses of vaccine required for a subject in a developed versus in 
developing countries may be different as has been shown e.g. for the dosage required for 
oral polio vaccine. The need for higher doses of the live oral cholera vaccine to be 
immunogenic  was seen  for children in Indonesia (81, 133) and Bangladesh compared to 
e.g. in the USA (120). In addition, general malnutrition and specific micronutrient 
deficiencies can also lead to immune suppression e.g. by inducing villous atrophy which 
leads to poor absorption of the vaccine components through the intestinal mucosa.   
 
Interventions to overcome hyporesponsiveness 
There have been several potential suggestions to overcome the problems of 
hyporesponsiveness such as delaying the vaccine schedule, to lessen the impact of 
maternal antibodies by separating vaccination from breast feeding to avoid the 
neutralization of antigen and inhibition by factors in breast milk, and by providing 
micronutrients e.g. zinc to boost immune responses (4). However, factors which may 
contribute to lowered immunogenicity of vaccines have not been well studied. Thus, 
although it is well established that zinc has an influence on multiple aspects of the 
immune system, including the normal development, differentiation, and function of cells 
belonging to both innate and acquired immunity (101, 134, 183), the mechanisms 
responsible for the positive effects of zinc treatment observed after vaccination as well as 
in diseases such as diarrhea, pneumonia and shigellosis have not been elucidated. Studies 
have also shown that zinc supplementation may  increase the immunogenicity of Dukoral 
in older children in Bangladesh (4) as well as in Norwegian adults (77), and Bangladeshi 
infants showed a serotype specific increase in  response to a pneumococcal conjugate 
vaccine when given zinc (107).  However, it is still unclear if zinc only promotes immune 
responses in zinc deficient individuals. Since zinc supplementation is now recommended 
for all the children with diarrhea in developing countries, it is particularly important to 
analyze the effects of zinc in children in relation to their individual zinc status. 
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Influence of the genetic diversity of the host on natural infection 
Expression of different ABO histo-blood group types has been shown to be associated 
with different risks of enteric infections (17, 18, 51, 58, 60, 65, 127, 137), presumably 
through differential expression of cell surface glycoconjugates that are used as receptors 
for pathogens infecting the intestinal mucosa. Blood group antigens are also expressed in 
the intestinal mucosa and in the meconium (78). Our recent study showed that ETEC 
diarrheal episodes were more common in children with blood group AB and A than in 
blood group O individuals (127).  A predisposition for dehydrating cholera has been seen 
in blood group O individuals (25, 51, 60, 175). 
 
In addition to the interaction with the ABO blood groups, interest has also been focused 
on the Lewis  blood group antigens which are present in mucosal secretions, on mucosal 
epithelial cells and naturally adsorbed on erythrocyte membranes (64, 82, 83, 88, 103). In  
the intestinal mucosa, the Lewis antigens are synthesized through a group of 
glycosyltransferases, which insert fucose residues in type 1 and type 2 oligosaccharide 
precursors (102, 182). The synthesis of Lewis antigens is dependent on the fucosyl 
transferase 2 and 3 genes (FUT2 and FUT 3) (Figure 2). If both genes are functional, the 
phenotype of the Lewis antigen is Le (a-b+), whereas individuals in whom the FUT2 
gene is not expressed are Le (a+b-). Failure to express both FUT2 and FUT3 will result in 
the less prevalent Le (a-b-) variant. The Lewis a-b+ phenotype is termed as secretor 
positive, while  the Lewis (a+b-) is termed as the  non-secretor status (33).  
 
Recent studies have shown that CFA/I expressed by ETEC binds to glycosphingolipids 
that are associated with Lewis a antigen (67). The glycosphingolipid binding capacity of 
CFA/I fimbriae resides in the major CfaB subunit protein and similar binding to 
glycosphingolipids has been demonstrated for CS1 and CS4 (12, 25, 67). However, 
whether children having specific Lewis blood group antigen phenotypes have different 
susceptibilities to diarrhea caused by ETEC expressing major colonization factors has not 
previously been investigated.  
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Figure 2. Biosynthesis pathways of the human Lewis histo-blood group antigens based 
on the type 1 and 2 precursors (Fuc, L-fucose; Gal, D-galactose; GlcNAc, N-
acetylglucosamine). 
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children is needed. The major aims of this thesis were therefore to determine the immune 
responses against natural ETEC disease, to examine the influence of host genetic factors 
on susceptibility to ETEC infections and to identify immune modulating factors on ETEC 
and cholera vaccine specific humoral and cellular immune responses, including dosing 
regimens, zinc supplementation and brief breast milk withdrawal. 
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AIMS 
The overall objective of this thesis was to identify different factors and vaccine 
administration regimens that may influence the immunogenicity of oral inactivated ETEC 
and cholera vaccines in young children and infants in developing countries. 
This includes: 
1. To examine the safety and immunogenicity of different doses of a prototype 
ETEC vaccine in Bangladeshi infants less than 2 years. 
 
2. To investigate the mucosal and systemic immune responses to one of the most 
common colonization factors, CS6, in patients with ETEC diarrhea.   
 
3. To determine the influence of Lewis blood group phenotypes of the host on the 
susceptibility to diarrhea with ETEC expressing different colonization factors. 
 
4. To study the safety and immunogenicity of, and different interventions that may 
improve antibody responses to, the oral inactivated cholera vaccine Dukoral in 
Bangladeshi children less than 2 years of age. 
 
5.  To analyze cholera vaccine specific T-cell responses in Bangladeshi infants and 
the influence of zinc supplementation on these responses. 
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MATERIALS AND METHODS 
Study sites 
Studies were either performed with participants from the ICDDR,B hospital in Dhaka, or in 
the Mirpur field area. The ICDDR,B is the only international research centre for enteric 
diseases located in a developing country. Mirpur is located in the urban metropolitan area 
of Dhaka city around 6-7 km from the ICDDR,B (Figure 3). The area of Mirpur is around 
90 sq km and is a densely populated area with 2.5 million inhabitants, corresponding to 
about 20% of the population in Dhaka City. We chose the Mirpur site for our studies 
since it is representative of a middle to low-income community, where we had experience 
in carrying out a large number of field and laboratory based studies over the last 15 years. 
Our field clinic is located at the centre of sections 10-12 of the Mirpur area. These 
sections cover about 10 sq km and have a population of around 0.3 million. The safety 
and immunogenicity studies of vaccines, as well as studies to determine the impact of 
interventions to improve the immune responses to cholera and ETEC vaccines in young 
children, were conducted in this study area (Paper I, IV & V). A birth cohort study has 
previously been performed in Mirpur (127), and was followed up in the present study to 
determine the relationship between infections with CFA/I-ETEC and Lewis blood group 
antigen expression by the host (Paper III).  
 
In addition, we also enrolled patients with ETEC diarrhea from the Dhaka Hospital at 
ICDDR,B to study immune responses against natural ETEC infection (Paper II). The 
majority of the immunological work was carried out at the immunology unit of the 
ICDDR,B, e.g. studies  utilizing  ELISA, enzyme linked immunospot (ELISPOT) and 
flow cytometric assays (FACS). Additional laboratory work, e.g. FACS and radioactive 
thymidine uptake assays for measuring T-cell proliferation, was also carried out at the 
Department of Microbiology and Immunology, the Sahlgrenska Academy at the 
University of Gothenburg, Sweden. 
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Figure 3. Study sites 
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Study participants 
Vaccination studies (Paper I, IV, V): For the ETEC and cholera vaccination studies, 
healthy male and female children aged from 6 months to 12 years were enrolled (Table 
2). Around 1200 subjects were screened and those with a history of gastrointestinal 
disorder, diarrheal illness in the past 2 weeks, febrile illness in the preceding week or 
antibiotic treatment at least 7 days prior to enrollment as well as children, weight-for-
length <−2SD of the median value of the National Centre of Health Statistics (NCHS) 
were excluded from the study. Also children found to be asymptomatically positive for 
any bacterial enteric pathogen, including ETEC or V. cholerae, were not included in the 
study. Finally, a total of 668 participants were enrolled in the different studies. The 
general health status of the children at the time of inclusion in the study was assessed by 
a study physician.  
 
Table 2: Characteristics of the different studies. 
  
Papers Number of 
subjects 
Type of study Study site 
Paper I 268 Clinical trial: open and blinded Community: Mirpur 
Paper II 46 Prospective: CS6-ETEC patients Hospital: ICDDR,B 
Paper III 462 Prospective and cross sectional: birth 
cohort 
Community: Mirpur 
Paper IV 340 Clinical trial: open Community: Mirpur 
Paper V 60 Clinical trial: open Community: Mirpur 
 
For establishment of methods for analysis of T-cell responses to the oral cholera vaccine, 
six healthy Swedish adults (mean age 34.75.3 years, 2 males) were also recruited at the 
University of Gothenburg (Paper V).   
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Lewis blood group study (Paper III): One hundred and seventy nine children, who had 
previously participated in a prospective community based birth cohort study (BC) on 
ETEC diarrhea (127), were enrolled again about 2 years later for determining their Lewis 
blood groups. To evaluate if children below two years of age had similar distribution of 
Lewis blood group phenotypes as the older children over four years of age, we also 
analyzed the distribution of Lewis antigens in a new group of 112 children less than two 
years of age from the same study area. To compare the distribution of Lewis blood group 
phenotypes in children and adults, we also studied specimens available from 171 mothers 
of the BC children. 
 
CS6 study (Paper II): To determine the mucosal and systemic immune responses to CS6 
expressing ETEC diarrhea, patients with acute watery diarrhea caused by ETEC as the 
only enteric pathogen were identified at the Dhaka hospital of the ICDDR,B. From 324 
ETEC positive patients, 46 patients with diarrhea caused by ETEC expressing CS6 or 
CS5 plus CS6 were recruited. In addition, apparently healthy age-matched adults and 
children, living in similar socioeconomic background were included as endemic controls.  
 
Written informed consent was obtained from the adult participants as well as from the 
parent or guardian of each child before screening and/or enrollment into the study. Assent 
was also taken from the children who were more 8 years of age. The studies were 
approved by the Research Review Committee (RRC) and Ethical Review Committee 
(ERC) of ICDDR,B. Ethical permission was also obtained from the Ethical Committee 
for Human Research at the University of Gothenburg.  
 
ETEC and V. cholerae antigens and strains used for the studies 
Purified CFs were prepared from disintegrated CFA-positive bacteria using standard 
ETEC reference strains (40) (Table 3). The purity and concentration of the preparations 
were determined by spectrophotometry and inhibition ELISA (136). In addition, sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting were carried out 
(136). Recombinant CS6 was obtained from Dr. Fredrick Cassels at the Walter Reed 
Army Research. It was prepared from a bacterial strain Escherichia coli (HB101) and a 
plasmid containing the four-gene operon necessary for CS6 expression was inserted by 
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recombinant techniques. The CS6 genes were cloned from ETEC strain E8875 (188).  
Purified CTB was obtained from SBL Vaccin, Stockholm, Sweden; it was highly pure 
and free of other antigens and bacterial products. A modified CTB molecule with a single 
amino acid substitution causing reduced binding to GM1 was also produced by 
recombinant techniques at the University of Gothenburg (74, 84, 140). The ETEC and V. 
cholerae strains used for purification of the antigens used in the studies are showed below 
(Table 3). 
 
Table 3. ETEC and V. cholerae strains used for antigen preparation and/or 
immunological analyses in studies 
 Strains Antigens Toxin types 
ETEC 325542-1 
258909-3 
H10407 
E11881A 
E1392-79 
278485-2 
E17018A 
VM75688 
334A/E29101A 
E8875/HB101 
E7476A 
E20738 A 
286C2 
CFA/I 
CFA/I 
CFA/I 
CS4+CS6 
CS1+CS3 
CS2+CS3 
CS5+CS6 
CS5+CS6 
CS7 
rCS6 
CS14 
CS17 
ST 
ST/LT 
ST/LT 
ST/LT 
ST/LT 
ST/LT 
ST/LT 
ST/LT 
ST/LT 
ST 
ST 
LT 
LT 
V. cholerae O1 Ogawa/X25049 
Ogawa/X25049 
569B 
569B 
LPS 
MP  
rCTB 
mCTB 
CTB 
CTB 
CTB 
CTB 
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Standard vaccination protocols (Paper I, IV & V) 
Both ETEC and cholera (Dukoral) vaccines were obtained from SBL Vaccin, Stockholm, 
Sweden. The ETEC vaccine (CF-CTB-ETEC) was composed of a total ~1×1011 CFU of 
five strains of ETEC. A full 6-ml dose contained 1 mg of rCTB plus ~1011 formalin-
inactivated bacteria of altogether five different ETEC strains producing CFA/I, CS1, 
CS2, CS3, CS4, CS5 (Box 2). The placebo used in the ETEC vaccination study (Paper I) 
consisted of ~1×1011 CFU of heat killed E. coli K-12 bacteria. Different volumes of the 
ETEC vaccine or placebo were formulated in buffer to prepare the different doses. A 
sachet containing 2.8 g of standard bicarbonate buffer (SBL) was diluted with 150 ml of 
water. Children over 6 years of age were administered the ETEC vaccine in 75 ml of 
buffer while those 2–5 years were administered vaccine with 50 ml of buffer  and infants 
6–17 month were administered the vaccine in 15 ml of buffer. 
 
The cholera vaccine (Dukoral) consists of ~11011 inactivated Vibrio cholerae O1 
bacteria plus 1 mg of rCTB (Box 1). Immediately before use, each dose of Dukoral was 
mixed with 20 ml of standard bicarbonate buffer.  
 
Each dose of two-dose regimens of either ETEC or cholera vaccines was given at 
intervals of 2 weeks. Both vaccines were given orally using a teaspoon to children 6-18 
month old. The study children were not allowed to eat 1 h before and 1 h after 
vaccination and were observed for 1 h in the field clinic after vaccination. Post 
vaccination surveillance for reactogenicity was carried out for 3 days after each 
vaccination. The guardians were requested to return to the health clinic at the field site 
with the children in an event of adverse events, in cases in which they needed clinical 
support. Each type of reaction was scored as mild (noticeable), moderate (affecting 
normal daily activities) or severe (suspending normal daily activities) as defined in an 
earlier study (117). All loose stools were tested for enteric pathogens including bacterial 
and common parasites. 
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Dose finding study for ETEC vaccine (Paper I) 
For the dose finding ETEC immunization protocol, we initiated an open pilot study in 
children 6 months to 12 years of age. The study was carried out in decreasing age groups, 
starting with 6–12-year old children followed by 2–5-year old and finally 6–17 month old 
children. The children aged 2 years and above received either a full, half or a quarter 
dose. Thereafter, 6–17 month old infants received a half or quarter dose of the vaccine in 
two different concentrations of bicarbonate buffer (half and full strength buffer) or a 
quarter dose of placebo in full strength buffer. 
 
Enhancement of cholera vaccine specific immune responses (Paper IV and V) 
To identify factors that may enhance the immunogenicity of  the oral inactivated whole 
cell cholera vaccine (Dukoral)  in young children and infants in Bangladesh, we studied 
the effects of different interventions, i.e. breast milk withholding for 3 h prior to and 1 
hour after immunization (Paper IV) and zinc supplementation starting 3 weeks before 
administration of the first dose of vaccine until 1 week after the second dose (Figure 4) 
(Paper IV and V) on the immune responses induced by  the vaccine. We also compared 
immune responses induced by the vaccine when given it with (i) the standard bicarbonate 
buffer (SBL Vaccin, AB), (ii) the same volume of water or (iii) without any additional 
fluid (Paper IV). 
 
 
 
 
 
 
 
 
Figure 4. Vaccination and zinc intervention schedule. ‘Vacc’ stands for vaccine, 
‘ZnVacc’ stands for zinc plus vaccine and ‘Zn’ stands for zinc only groups; in addition 
‘D’ stands for day. 
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Collection of clinical samples (Paper I-V) 
For the vaccination studies, both stool (5 g) and venous blood (1.5- 3 ml) were collected 
from each subject prior to immunization and then 7 days after the first and 7 days after 
the second dose of vaccination (Paper I, IV & V). Baseline samples were also collected 
prior to initiation of as well as at the end of the zinc supplementation (Paper IV & V). In 
addition, to determine cholera vaccine specific T-cell proliferation, 50 ml of blood was 
collected from adult Swedish volunteers before and 7 and 14 days after the second dose 
of vaccine for validating the novel flow cytometric technique with traditional radioactive 
thymidine incorporation methods (Paper V).  
 
To determine the immune responses to CS6 expressing ETEC diarrhea, stool samples (5 
g) as well as venous blood (5-10 ml) were collected from the children and adult patients 
at the acute stage (~day 2) as well as at different time points (days 7 and 21) after onset 
of infection (Paper II). Blood and stool samples were also collected once from healthy 
age matched control subjects.  
 
For determining the relation between Lewis blood groups and ETEC infection, venous 
blood (3 ml) and saliva samples (500 l) were collected from children of a previous birth 
cohort (BC) study (127), who were 4-6 year of age at the time for the renewed sample 
collection, and from newly recruited children from the same area, who were less than 2 
years of age, as well as from the mothers of the BC children (Paper III).  
 
Identification of ETEC and other enteric pathogens in stool (Paper I-V) 
The monthly as well as diarrheal stool samples collected from the participants in the BC 
and CS6 studies were analyzed for ETEC as previously described using GM1-ELISA for 
LT and ST expression and dot blot assays for analysis of CFs including CS6 (127, 151) 
(Paper II and III). The stool samples were also cultured for other enteric pathogens, e.g. 
Vibrio cholerae O1/O139, Salmonella, Shigella and Campylobacter spp., as well as 
analyzed for  rotavirus by ELISA (186) and tested by direct microscopy to detect cyst and 
vegetative forms of parasites and ova of helminthes (186). Stools from healthy children 
were similarly screened, and those subjects that were found to be negative for enteric 
pathogens were recruited as controls for CS6 studies.  
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Determination of  antibody responses in serum or plasma (Paper I, II, IV & V) 
Serum separated from blood, or plasma samples collected from the top of the Ficoll 
gradient, were stored in aliquots at -20°C until ELISA was performed. Specific IgA and 
IgG antibody response to CFs and rCTB were measured by ELISA (68, 143). To 
determine immune response to Dukoral, plasma samples were tested for vibriocidal 
antibodies using a V. cholerae O1 El Tor Ogawa strain, X25049 as the target bacteria 
(125) (Paper IV & V). Plasma samples were also analyzed for LPS specific antibodies of 
both IgA and IgG isotypes (126). Antibody titers were calculated using the computer-
based program MULTI (DataTree Inc., USA). 
 
Determination of T-cell responses (Paper V) 
For determining the T-cell responses against cholera vaccine in young children by T-cell 
proliferation assays, we adopted a new flow cytometric T-cell response assay, the flow 
cytometric assay of specific cell-mediated immune response in activated whole blood 
(FASCIA) (154) (Figure 5). This assay allows analysis of T-cell proliferation in response 
to stimulation with specific antigens using small volumes of whole blood. Briefly, after 
dilution of heparinized blood, cells were cultured at 37°C in the presence or absence of 
the following antigens: mCTB (10 µg/ml), cholera membrane proteins (chMP, 10 µg/ml 
and 1 µg/ml), and positive control antigen phytohaemagglutinin (PHA, 1 µg/ml, Remel, 
USA). After 6 days, cell culture supernatants were collected and the cells were stained 
with fluorescent tagged antibodies (anti-CD3-APC, anti-CD4-PerCP and anti-CD8-FITC; 
BD, USA). After lysing the red blood cells, samples were washed and fixed in 
paraformaldehyde and were analyzed using a FACSCalibur machine (BD, USA) and the 
FlowJo analysis software (Tree Star Inc., USA). The numbers of blast forming 
CD3+CD4+ T cells acquired in each sample during 120 seconds were determined and the 
results were expressed as the numbers of CD4+ T-cell blasts/100 l of sample. In 
addition, we compared and validated the FASCIA technique with a standard thymidine 
incorporation assay (95) in initial setup experiments on vaccinated Swedish volunteers. 
The concentrations of different cytokines, e.g. IFN- and IL-13 were measured in culture 
supernatants using ELISA as previously described (95), and the levels of IL-4, IL-5, IL-2, 
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IL-10 and TNF- by the cytometric bead array (BD Pharmingen) as recommended by the 
manufacturer. 
 
 
 
 
Figure 5. Schematic diagram describing the steps of the FASCIA assay for detection of 
T-cell responses. 
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Determination of mucosal antibody responses  (Paper I, II & IV) 
Peripheral blood mononuclear cells (PBMC) were isolated by gradient centrifugation on 
Ficoll-Isopaque (Pharmacia, Sweden) from heparinized venous blood for determining the 
specific antibody responses by antibody-secreting cells (ASC) and antibody in 
lymphocyte supernatant (ALS) at different time points for patients (Paper II) as well as 
for vaccinees (Paper I, IV). For determining anti-CS6 fecal IgA responses, fecal extracts 
were prepared and aliquots were frozen at -70°C until ELISA was conducted (117). 
 
To assess ASC responses, PBMCs were assayed for total and ETEC-specific numbers of 
ASC by the two-color enzyme-linked immunospot technique (ELISPOT) (31, 69, 115). 
Cells secreting antibodies of the IgA isotype against CFA/I antigen and rCTB (Paper I) as 
well as CS6 (Paper II) were determined as described (31, 69, 115). Numbers of antibody 
secreting cells (per 107 PBMC) against the different antigens were determined; a post 
dosing value of ≥10 ASC/106 was considered as a significant response (144). 
 
ALS responses were determined for CFs as well as CTB and LPS (Paper II & IV). 
PBMC (107 cells per ml) from patients and healthy controls and also from children of the 
vaccination study were cultured in 24-well tissue culture plates for 48 h in 5% CO2, and 
supernatants of the cultures were stored at -70°C and tested for antibody responses by 
ELISA (20, 100, 116, 126). Pooled human sera from previous studies on ETEC vaccinees 
and cholera patients were used as controls to adjust for inter-assay variations. 
 
To assess fecal IgA antibody responses, the total IgA content in fecal samples was 
determined by ELISA, using pooled human Bangladeshi milk with a known IgA 
concentration (1 mg/ml) as the standard (2, 185). Specific IgA responses were determined 
by using the conventional ELISA technique as described (2, 185). The fecal antigen-
specific IgA responses were expressed as the interpolated IgA ELISA titer per g total 
IgA; specimens with total IgA contents of <10 g/ml, acute and convalescent specimens 
whose total IgA contents varied more than 10-fold, and acute and convalescent 
specimens with specific IgA titers of <1 were not included in the analyses (126, 128).  
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Determination of Lewis blood group phenotypes (Paper III) 
Lewis blood groups were typed using fresh whole blood in an agglutination test assay 
according to the manufacturers’ instruction (Figure 5) as well as in saliva samples by a 
dot-blot immunoassay as  described previously (111) (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic diagram showing the steps of Lewis blood group determination 
using whole blood and salivary samples. RBC stands for red blood cells. 
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Determination of zinc levels (Paper IV and V) 
Serum zinc levels were determined at the baseline for all vaccinated children and at the 
end of the study period for children given zinc only or zinc plus vaccine. Serum zinc 
levels were measured by atomic absorption spectrophotometry. Zinc deficiency was 
defined as values ≤0.7 mg/L (49). 
Statistical analysis  
Data analyses were carried out using the SigmaStat 3.1 program (SPSS Systat Software, 
Inc.). Children with 2 fold rises in serum or mucosal antibody levels to CFs, CT or LPS 
in ELISA and 4 fold increase of vibriocidal antibodies in serum after vaccination as 
compared to before immunization were considered as responders (27, 70, 71). For 
determining the T-cell responses, children with 2 fold increase in T-cell counts or IFN- 
levels compared to the responses before vaccination were considered as responders. CF-
specific ASC responses of 10 ASC/106 PBMC on day 7 (post-infection) was considered 
positive. Responses were also compared where necessary to healthy controls. Cumulative 
responder frequency was defined as the responses after intake of the first and/or second 
dose of vaccine in vaccination studies, and at early and/or late convalescent responses 
compared to acute stage responses in patient studies. Results are expressed as geometric 
mean titer (GMT) and standard error of mean (SEM). Paired samples were assessed by 
the Wilcoxon signed rank test, non-paired samples by the Mann–Whitney U-test and 
proportion of responses using the χ2 or the Fisher exact test. In addition, the Chi-Square 
or Fisher Exact Tests were also used for determining the Lewis phenotypes with CFA/I 
group ETEC diarrhea (Paper III). P values ≤0.05 were considered to be statistically 
significant.  
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RESULTS AND COMMENTS 
Safety and immunogenicity of reduced doses of ETEC vaccine in 
Bangladeshi infants (Paper I)  
In previous phase I studies in Bangladesh, the CF-CTB-ETEC vaccine was found to be 
safe and immunogenic in adults as well as in children 3–9 years of age (129). It was also 
well tolerated in children, 18–36 months of age and gave rise to robust systemic and 
mucosal IgA antibody responses (117). Since ETEC diarrhea is most common in younger 
children (127), the vaccine was also evaluated in a younger age group 6-17 months of 
age. A randomized, double blind placebo-controlled study carried out in this age group 
showed that a full dose of the ETEC vaccine gave rise to adverse events in the form of 
vomiting and hence the study was terminated before being completed (159).  
 
Therefore, studies were undertaken to evaluate whether a lower dose of the ETEC 
vaccine would be safe and immunogenic in Bangladeshi infants. For this purpose, a dose 
finding study was first carried out in 2-12 year old children, to determine the 
immunogenicity of a full, half and a  quarter dose of the ETEC vaccine. These analyses 
showed comparable plasma antibody responses to vaccine specific antigens against the 
different doses of vaccine in these children. Thereafter, half and quarter doses were tested 
in children 6-17 months of age showing that the quarter dose was safe and gave almost 
comparable immune responses as the higher doses. Based on these results, a randomized 
double-blind placebo controlled trial of the reduced quarter dose of the vaccine was 
carried out in infants. The latter study showed no differences in symptoms between the 
vaccinees and the placebo recipients, confirming that a quarter dose of the vaccine was 
safe in children aged 6-17 months. The studies also showed that post-vaccination immune 
responses in the 6-17 month old children were comparable after a half and quarter doses 
of vaccine.  
 
We also found that response rates and magnitude of responses to CFA/I were somewhat 
lower in the infants than in the older children, whereas responses to CTB were 
comparable or even slightly higher in the youngest age group given a quarter dose 
(Figure 7).  
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Figure 7. Immune responses after two quarter doses of ETEC vaccine in the three 
different age groups. ‘0’ indicates the ‘pre-vaccination’ and ‘2’ indicates ‘post-
vaccination’ titers. GMT indicates geometric mean titer. Asterisks indicate significant 
differences between pre- and post- vaccination levels. 
 
 
These findings suggest that optimal doses of vaccine for children in developing countries 
may not be the same as for adults in developed or developing countries. Thus, our results 
suggest that vaccines need to be evaluated independently in different populations and in 
different doses to identify optimal dosage for the respective target groups.  
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Mucosal and systemic immune responses to CS6-expressing ETEC in 
hospitalized diarrheal patients (Paper II) 
Based on the high prevalence of CS6 positive ETEC in different regions of the world, the 
antigenicity of CS6 has been evaluated as a candidate vaccine antigen expressed by live 
attenuated strains (172, 173) or recombinantly produced, and administered by different 
routes (19, 42, 172, 189). In all these studies, immune responses against CS6 have been 
weak. Hence, we studied the immunogenicity of CS6 after natural infection to determine 
the levels of anti-CS6 responses in patients with CS6 positive ETEC.  
 
Identification of CS6-ETEC patients  
To determine the natural immune responses to CS6, both adult and children patients 
infected with CS6 expressing ETEC were studied for systemic and mucosal immune 
responses to CS6 using different immunological techniques, and for analyzing different 
clinical specimens. Patients with history of diarrhea ranging between 2 and 72 h prior to 
arrival at the hospital and with confirmed CS6 positive ETEC (CS6 alone or CS6 co-
expressed with CS5)  as the only pathogen in stool were enrolled for the study;  the adult 
patients suffered more from severe dehydration compared to the children (46% vs. 11%). 
The CS6 only ETEC strains were mostly of the ST only phenotype (85%) and less of the 
LT/ST phenotype (15%), whereas the CS5+CS6 strains were equally distributed among 
ST only (48%) and LT/ST (52%) toxin types.  
 
Immune responses to CS6  
Studies of CS6-specific ASC responses at the acute (day 2) and early convalescent stage 
(day 7) of diarrhea showed ~30-fold higher ASC responses of the IgA isotype (P=0.005) 
(Figure 8 A) and also weak responses of IgG and IgM isotypes by day 7 compared to at 
the acute stage. Response rates of 89-100% were seen in the IgA isotype in children and 
adults, and all the patients showed IgG responses to CS6 by day 7. Similar trends of IgA 
responses to CS6 were also seen using the ALS assay. ASC or ALS responses in healthy 
controls were negligible in both the IgA and IgG isotypes compared to those seen at day 
7 post-onset in the patients (P<0.001). CS6-IgA antibody responses in serum were also 
seen in patients infected with ETEC expressing CS6 (Figure 8B). The IgA antibody 
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responses had declined by day 21 as compared to the responses seen on day 7 (P<0.001). 
However, IgG antibodies to CS6, which peaked at the early convalescent stage, remained 
elevated up to late convalescence. Comparable antibody responses to CS6 were seen in 
children and adults with ETEC diarrhea. In addition, both children and adults infected 
with CS6 expressing ETEC responded with CS6 specific IgA antibodies in stool by day 7 
of infection (Figure 8C); the day 7 antibody levels in the patients were significantly 
higher than the antibody levels seen in stool specimens from healthy controls (P<0.001).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, the results show that CS6 is immunogenic and give comparable immune 
responses in children and adults infected with ETEC irrespective of whether CS6 is 
Figure 8. CS6-specific systemic and mucosal IgA responses at the acute (d2) and at 
early (d7) convalescent stage (GMT+SEM). Both children and adults including 
individuals infected with CS6 alone or CS6 together with CS5 are included in these 
analyses.  
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expressed alone or together with CS5, and that those responses can be measured in 
mucosal and systemic clinical specimens. Thus, substantial antibody responses of both 
the IgA and IgG isotypes were induced in plasma as well as in ASCs and ALS 
specimens. Highest immune responses in serum were found at the early convalescent 
stage and these levels had decreased already within a couple of weeks in most instances. 
Thus, our study gives evidence that natural ETEC infection gives rise to robust anti-CS6 
responses and that it may be possible to induce such responses by a vaccine expressing 
sufficient amounts of CS6 in immunogenic form. 
 
Children with Lewis (a+b-) blood group are more susceptible to 
diarrhea caused by ETEC expressing CFA/I group fimbriae (Paper III)  
CFA/I has been shown to bind to blood group antigens, particularly Lewis a and related 
glycolipids, that may be expressed on intestinal epithelial cells in humans (67). To 
evaluate if individuals with certain Lewis blood groups, e.g. Lewis (a+b-), are more 
susceptible to infection with ETEC expressing certain CFs, a study was carried out in 
Bangladeshi children to determine the possible association between Lewis phenotype and 
susceptibility to ETEC expressing the CFA/I group fimbriae. These studies were 
undertaken as a follow up of a previous birth cohort study (127). As many as 179 
children of the 254 children participating in the original BC study were eligible for follow 
up.  
 
Determination of ETEC infection in BC children 
ETEC had been the cause of at least one symptomatic diarrheal episode in 56%, and one 
or more asymptomatic ETEC infection in 37% of the children in the original birth cohort. 
Among the 13 colonization factors searched for in the ETEC strains isolated from the BC 
children, CFA/I, CS3 and CS6 were the major ones identified in isolates from 
symptomatic as well as asymptomatic stool samples. The frequencies of ETEC strains 
that had been isolated from diarrheal stool samples and that expressed CFA/I, CS3 (alone 
or together with CS1 or CS2) and CS6 (alone or together with CS5) were 9.8%, 7.5% and 
23.0%; for asymptomatic stool samples the frequencies were 7.7%, 4.0% and 11.4%. 
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Lewis blood group phenotypic distributions  
Lewis blood group phenotypes were determined by a dot blot immunoassay using saliva 
samples and by a tube agglutination test using fresh red blood cells (RBC) from the 179 
BC children aged ≥4 years of age, and also from a group of 112 younger children 
(aged<2 years) from the same area to evaluate if Lewis phenotypes had been comparable 
at the time for ETEC infection, i.e. before 2 years of age. When using the saliva test, 
similar frequencies of Le (a-b+) and Le (a+b-) were found in the older and younger 
children as well as in adults (Figure 9). However, when analyzing Lewis phenotypes with 
the RBC agglutination test, 17 of the younger control children were found to have the Le 
(a+b+) phenotype. Since it has been shown that the Le (a+b+) RBC phenotype converts 
to the Le (a-b+) phenotype by the age of two years (33), these children were included in 
the Le (a-b+) group. Our findings support that saliva samples can be used for 
determination of Lewis phenotypes even in infants as well as in large population based 
studies.  
 
 
 
 
 
 
 
  
 
 
 
 
Figure 9: Distribution of Lewis blood groups in Bangladeshi children of different age 
groups and adults as determined by salivary test. 
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Lewis blood group phenotypes and association with ETEC expressing major CFs 
and different toxin profiles 
When analyzing the distribution of symptomatic and asymptomatic ETEC infections in 
relation to Lewis antigen phenotypes of the BC children, we observed that the Le (a+ b-) 
children were significantly more prone to have symptomatic (71%) than asymptomatic 
ETEC infections (29%) (P<0.001). In contrast, the prevalence of symptomatic (56%) and 
asymptomatic (44%) ETEC infections did not differ significantly in the Le (a-b+) 
children. In addition, when analyzing for a possible association between Lewis phenotype 
of the BC children and infections with ETEC expressing CFA/I group fimbriae (CFA/I, 
CS14 and CS17), we observed a significantly higher incidence of symptomatic ETEC 
infections in the Le (a+b-) than in the Le (a-b+) group (P=0.032); this relationship was 
even higher for children infected with ETEC expressing CFA/I-group fimbriae in 
combination with CS3, i.e. CS1+CS3 and CS2+CS3 (P<0.001) (Figure 10). When 
analyzing the association between Le (a+b-) phenotype and ETEC expressing CFA/I 
only, no significant relationship was found, probably due to too low number of such 
infections in the study group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Association between Lewis blood group phenotypes and symptomatic ETEC 
expressing CFA/I alone or CFA/I group fimbriae alone and in combination.  
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When studying the relationship between infections with ETEC expressing CS5+CS6 or 
CS6 only and Lewis blood group phenotypes, we did not find any significant 
relationship, either for children with symptomatic or asymptomatic infections. Similarly, 
no association between the Lewis blood group phenotype and the toxin profile of the 
ETEC strains isolated from the BC children was found. 
 
Combined association of ABO and Lewis blood group with ETEC infection  
We have previously shown that ETEC diarrheal episodes were more prevalent in children 
of blood group A and AB than of other blood groups (127). When analyzing for the 
occurrence of ETEC diarrhea in BC children with different combinations of Lewis blood 
group phenotypes and ABO blood groups, we found that among the blood group A 
children, Le (a+b-) children were more prone than those with Le (a-b+) to ETEC diarrhea 
(82% vs. 43%), i.e. children with Lewis secreting blood group antigens were less 
susceptible to symptomatic infection, although this difference did not reach statistical 
significance (P=0.061).  
 
In summary, our results in children support previous experimental studies of specific 
binding of CFA/I group fimbriae to certain glycosphingolipids (67). This study is also the 
first one to suggest that a relationship exists between Lewis blood group (a+b-) 
phenotype, i.e. non-secretor status, and susceptibility to a bacterial enteric infection.  
 
Studies of immune responses to cholera vaccine in young Bangladeshi 
children and the effect of different interventions (Paper IV & V) 
First, the safety and immunogenicity, as well as possible interventions to increase the 
immunogenicity of the licensed oral cholera vaccine Dukoral was evaluated in 6-18 
month old Bangladeshi children. In a second smaller study, we also investigated if 
immunization with the oral cholera vaccine may induce specific T-cell responses in 
children 10-18 month old and whether zinc supplementation may enhance such 
responses. 
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Cholera vaccination and evaluation of reactogenicity 
In these studies, a total of 400 Bangladeshi infants from Mirpur were enrolled for studies 
of safety and immunogenicity of differently administered oral cholera vaccine (Dukoral) 
(Table 2). Two different age groups of children, 6-9 month and 10-18 month, were given 
two doses of vaccine either in different vaccine formulations or after breast milk 
withdrawal or zinc supplementation (Figure 4). All children were breast fed and healthy 
according to study requirements and the average baseline zinc levels did not differ 
significantly among the different intervention groups. Surveillance for possible 
reactogenicity during 3 days after each vaccine administration did not reveal any adverse 
events either in children of the different age groups or after vaccination in combination 
with any of the interventions tested.  
 
Systemic and mucosal antibody responses 
In the initial large cholera vaccination study (Paper IV), significantly increased 
vibriocidal antibody responses were observed both in the older and in the younger age 
groups of children after intake of two oral doses of Dukoral administered with standard 
buffer; the overall response rates were comparable in the two age groups (56% vs. 57%).  
However, whereas the vibriocidal responses were significantly higher after intake of the 
second dose in the younger children, they were not significantly increased after intake of 
the second as compared to after the first vaccine dose in the older age group. Both age 
groups of children responded with higher rates and magnitudes of antitoxin responses 
after intake of the second than after the first dose of vaccine, both with CTB-IgA as well 
as CTB- IgG responses (P<0.001). Similar vibriocidal as well as antitoxin antibody 
responses were also obtained in the second, smaller Dukoral study in 10-18 month old 
children compared to the first study (Paper IV and V). The post vaccination IgA (25-
34%) and IgG (13-34%) responses to LPS were lower than to CTB in all study groups in 
both studies.  
 
We also compared the immune responses with different vaccine formulations (Paper IV). 
Except for the significantly lower antitoxin responses when using water or not adding any 
fluids as compared to standard buffer formulation in the older, 10–18-month old children, 
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comparable antibody responses were observed in children receiving Dukoral with these 
three formulations.  
 
Vaccine specific mucosal antibody responses were also determined in ALS specimens 
using ELISA (Paper IV). Increased CTB specific IgA ALS antibody responses, that were 
comparable in both age groups, were observed after intake of the first (P<0.05) and 
second vaccine dose (P<0.05) in all study groups (cumulative responder frequency, 72-
88%). No differences in ALS antitoxin IgA titers were observed between the different 
intervention groups. Responses to LPS in IgA ALS assay were low (~30% responder 
frequency). These results show that a full dose of Dukoral is safe and immunogenic also 
in very young children.  
 
Cellular immune responses 
Since T-cell responses are difficult to measure in children due to the limited volume of 
blood that is available for testing, we adopted the FASCIA method that only requires 
small volumes of blood for our studies (Paper V). Initial establishment of the FASCIA 
technique for analysis of T-cell responses to the oral cholera vaccine was performed 
using blood samples collected from the adult Swedish volunteers before and after 
vaccination with Dukoral. In the initial validation assay in adult Swedish volunteers, we 
found robust T cell blast responses to a variant CTB molecule (mCTB) with reduced 
GM1 binding capacity in comparison to rCTB. Therefore, this mCTB molecule was used 
in forthcoming experiments. We also compared the FASCIA method with traditional 
thymidine incorporation assay and found good agreement between the two methods when 
assessing T-cell responses to the cholera vaccine. Concentrations of different cytokines 
were measured in culture supernatants from the FASCIA cultures using ELISA as well as 
by the cytometric bead array technique. 
 
After two doses of Dukoral, mCTB gave rise to significantly increased numbers of CD4+ 
T-cell blasts compared to the pre-vaccination levels (P=0.011) whereas the proliferative 
T-cell response to a membrane protein preparation of V. cholerae O1 bacteria did not 
differ significantly from the baseline responses in any of the vaccination groups (P>0.05) 
(Figure 11).  
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Figure 11. Vaccine specific T-cell responses to mCTB and cholera MP (chMP) in 
Bangladeshi children before (pre) and after (post) intake of two doses of Dukoral. 
Asterisk indicates significant rise of the T-cell response (P<0.05).   
 
Vaccination also induced increased production of IFN- in response to mCTB stimulation 
compared to in secretions collected before vaccination (P<0.05). No detectable levels of 
other cytokines (IL-4, IL-5, IL-2, IL-10, IL-13 and TNF-) were found in the culture 
supernatants.  
 
The results show that the oral cholera vaccine can induce a vaccine specific Th1 T-cell 
response to mCTB in young children. However, lack of responses to chMP may be due to 
the presence of a large number of cross reacting antigens in these primed children, who 
were previously infected with other enteric pathogens.   
 
Interventions to improve vaccine specific antibody responses 
The younger, 6-9 month old infants, who were temporarily not breast fed i.e. for 3 hours 
before vaccination, showed comparable vibriocidal responses as the infants, who received 
vaccine in the standard buffer formulation (Paper IV). In the older, 10-18 months old 
children, however, withholding of breast milk resulted in significantly higher vibriocidal 
antibody responses, both with regard to magnitude and responder frequency than in 
children given vaccine by the standard protocol (P<0.001). This difference in the two age 
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groups may be due to delayed emptying of breast milk from the intestine of the younger 
infants compared to the older children. Withholding of breast milk had no influence on 
antitoxin immune responses in either of the two age groups (Paper IV).  
 
Supplementation with zinc resulted in amplification of the vibriocidal responses in the 
older children after intake of two doses of vaccine. This result was first obtained in the 
large Dukoral study (Paper IV) and was later confirmed in the second cholera vaccine 
study (Paper V, Figure 12). About 3-4-fold higher vibriocidal responses were observed in 
the zinc supplemented vaccine group compared to in the groups given only the standard 
vaccination in both studies (P<0.001). However, zinc had no influence on vibriocidal 
antibody responses in the younger age group (Paper IV). The reason for the differences 
observed in the different age groups could be because the younger children were less zinc 
deficient than the older ones. Another explanation may be that the immunomodulating 
effect of zinc can only be seen in children whose immune system is more developed and 
receptive to the effect of zinc supplementation. Zinc supplementation did not affect the 
antitoxin immune responses in either age group (Paper IV and V). 
 
 
 
  
 
 
 
 
Figure 12. Effect of zinc supplementation on vibriocidal antibody responses to cholera 
vaccine in 10-18 month old Bangladeshi children before (pre) and after (post) intake of 
two doses of Dukoral (Paper V). ‘Vacc’ stands for vaccine and ‘ZnVacc’ stands for zinc 
plus vaccine groups. Asterisks indicate significant rise of the vibriocidal antibody 
response in pre- versus post-vaccination samples (P<0.05).     
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We also studied if zinc supplementation influences antibody responses differently in zinc 
deficient and zinc sufficient children (Figure 13). The effect of zinc on the vibriocidal 
responses was primarily seen in zinc deficient children, since zinc supplementation 
significantly enhanced the responses in this subgroup, whereas the responses among zinc 
sufficient children were comparable with and without zinc supplementation. Among the 
zinc deficient children, the responder frequencies increased from 54% to 89% as a result 
of the supplementation (P<0.05), whereas the responder frequencies were comparable in 
the zinc sufficient children with and without zinc supplementation (71% vs 78%). 
However, no significant influences of baseline zinc status or zinc supplementation were 
observed on the CTB- or LPS-specific antibody responses.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Zinc deficient children show higher vibriocidal antibody responses (fold 
increases) to oral cholera vaccine after supplementation with zinc. ‘ZnDef’ stands for 
zinc deficient and ‘ZnSuf’ for zinc sufficient children. ‘Vacc’ stands for vaccine and 
‘ZnVacc’ for zinc plus vaccine groups. Asterisk indicates significantly higher vibriocidal 
antibody response (P<0.05) in the ZnDef than ZnSuf group after zinc supplementation 
and ‘ns’ indicates no significant difference between groups.     
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Our studies have thus documented that brief temporary breast milk withdrawal as well a 
zinc supplementation for a couple of weeks in zinc deficient children may enhance the 
antibacterial immunogenicity of the oral cholera vaccine, but that these effects were 
restricted to children above 9 months of age.  
 
Influence of zinc on vaccine specific cellular responses 
We also evaluated the influence of zinc supplementation on T-cell activation in 10-18 
month old children. Supplementation with 20 mg of zinc before and during the 
vaccination period did not affect the level of T-cell proliferation induced by mCTB 
(P>0.05), but enhanced the production of IFN- more than 4-fold (P=0.008) (Figure 14). 
However, we could not detect any clear differences in T-cell responses between children 
who were zinc sufficient or zinc deficient at the start of the study. This may be due to the 
small sample size of each subgroup of children and further larger studies might reveal a 
difference between zinc deficient and sufficient children. 
 
 
 
 
 
 
 
 
 
Figure 14. Effect of zinc supplementation on IFN- T-cell responses to mCTB in 
Bangladeshi children before (pre) and after (post) intake of two doses of Dukoral. ‘Vacc’ 
stands for vaccine and ‘ZnVacc’ stands for zinc plus vaccine groups. Asterisks indicate 
significant rises of the IFN- response to vaccination (P<0.05).     
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In summary, these are the first studies to show that Dukoral is safe and immunogenic in 
children as young as six months of age. The vaccine induced both antibody and T-cell 
responses in these young children. Simple interventions such as changing the breast 
feeding pattern in relation to vaccination or increased intake of zinc induced significant 
increases in the vibriocidal antibody responses, which are indirect markers of immunity. 
The effect of zinc was not restricted to the B-cell responses but also influenced the T-cell 
responses and induced increased IFN- production in response to vaccination.  
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GENERAL DISCUSSION 
The main goals of these studies were to evaluate safety, immunogenicity, optimum 
immunization regimens and efforts to improve vaccine responses to oral cholera and 
ETEC vaccines in young children in a developing country. For these purposes, two oral 
inactivated whole cell vaccines, containing the same CTB component against ETEC 
diarrhea and cholera, respectively, were evaluated in young children less than 18 months 
of age in Bangladesh.  
 
Due to adverse reaction in the form of vomiting after taking the ETEC vaccine in 6-17 
month old children, we lowered the dose of vaccine given to this age group. We have 
shown that a lowered, quarter dose of ETEC vaccine was immunogenic in children 6 
months to 12 years of age.  Both antitoxic and antibacterial antibody response rates to a 
quarter dose of the vaccine were also almost comparable to those seen to the full dose of 
the ETEC vaccine in this and earlier studies carried out in Bangladesh and Egypt (57, 
117, 145). However, the magnitudes of the antibacterial (anti-CF) antibody responses to 
the quarter dose were somewhat lower than to the full dose in the 6-17 months old 
children. Furthermore, the magnitudes of the anti-CF responses were generally lower in 
the infants than in children >2 years of age to all doses of vaccine in this study  as well as 
when compared to responses in previous studies in Bangladesh (117, 129). Similar 
findings were found in Egypt where lower post-immunization titers to the ETEC vaccine 
were seen in young infants (145) compared to in older children (57, 144).  
 
The full dose of Dukoral was not only safe but also immunogenic in young children less 
than 18 months. We observed similar response rates for vibriocidal antibodies as in a 
previous study in older children (4). However, like the ETEC vaccine studied in different 
age groups, lower magnitudes of responses were seen in young (6-18 month) than in 
older children in spite of that a higher vaccine dose per weight of the child was given to 
the youngest (4, 118). An age descending, lower magnitude of immune response has also 
been seen to the live oral attenuated vaccine, Peru-15, in Bangladesh (120). This is 
probably due to previous priming of older children, resulting in higher responses, as well 
as to a more mature immune system in these children. 
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Both the ETEC and cholera vaccines gave rise to comparable mucosal and systemic 
vaccine specific immune responses to certain common component as well as to 
homologous LPS. Thus, both vaccines induced strong, comparable levels of systemic IgA 
and IgG antibody responses to CTB and poor antibody responses to LPS. The ETEC 
vaccine also induced enhanced, significant antibody responses against the bacterial CFs 
and Dukoral induced significant antibacterial, i.e. vibriocidal antibody responses in 
serum.  
 
Although B-cell responses to both cholera and ETEC vaccines have been extensively 
investigated, the involvement of T cells in protection against cholera has to date not been 
thoroughly investigated. In this study, we also measured cholera vaccine specific T-cell 
responses in 10-18 month old children and our results confirm that Dukoral can induce 
CD4+ T-cell responses against CTB. The stimulated T cells primarily secreted the Th1 
type cytokine IFN-, but not measurable levels of the Th2 cytokines IL-13, IL-4 or IL-5. 
The responses were clearly detectable one week after administration of the second 
vaccine dose, a time point known to be optimal for analysis of ASC response in 
peripheral blood (32). These findings are also consistent with a previous study 
demonstrating the presence of increased numbers of IFN- producing cells in the small 
intestine of adult volunteers one week after administration of the oral cholera vaccine 
(130). However, the present results reveal for the first time the capacity of Dukoral to 
induce a vaccine specific Th1 T-cell response in young children, which are likely to 
influence the B-cell responses induced by infection and vaccination.  
 
Vomiting was observed when the ETEC vaccine was tested in a full dose in children 6-17 
month old, but was not seen in those given a quarter doses. The reason for observing 
more side effects to the full dose of ETEC vaccine in infants than in older children (116, 
169, 180) may be directly related to the differences of nutritional status as well as the size 
of the children. Generally speaking, children in Bangladesh are smaller in size and lower 
in weight than children of the same age group in developed countries (160). Even 
children in Egypt, in whom some symptoms of vomiting were observed, had better 
nutritional status than the Bangladeshi children (145). In contrast, the same number of V. 
cholerae bacteria as used as in the ETEC vaccine could be given without causing any 
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adverse events even to 6 months old Bangladeshi infants.  An interesting observation was 
that there was also reactogenicity in recipients given a full dose of the E. coli K-12 
placebo and that a quarter dose of the placebo resulted in decreased frequency of 
vomiting. This suggests that the number of E. coli bacteria needs to be decreased when 
used for infants, probably due to the lipid A bound 3-deoxy-D-manno-octulosonic acid 
content of LPS in E. coli  which is believed to be higher than V. cholerae O1 and that 
might cause this differing toxicity (142, 161). 
 
One limitation to the use of mucosal vaccines is that these vaccines are less immunogenic 
in children than adults, which is thought to partly be a result of immature lymphocytes 
and antigen presenting cells (47, 174, 190). In addition, there are a number of factors that 
may be accountable for inducing lowered immunological and/or protective efficacy in 
young children in developing countries. These include the nutritional, in particular the 
micronutrient status of the children, environmental factors as well as differences in 
genetic makeup of populations which can be contributing elements for modulating 
responses and can result in less than optimal efficacy of vaccines. In addition, the levels 
of trans-placental transferred maternal antibodies and frequent breast-feeding practices 
may also be responsible for this hyporesponsiveness (37, 132, 178). However, factors 
which may contribute to the lowered immunogenicity of vaccines have not been well 
studied. In this thesis, the effect on the immunogenicity of the oral cholera vaccine by 
different interventions, e.g. by altering the formulating buffer, by modification of the 
breast feeding pattern and by supplementation with zinc, is documented. 
 
Oral cholera vaccines have generally been formulated in buffers to counteract the gastric 
acidity of the stomach and to protect the acid perishable CTB component from 
denaturation. However, sometimes buffers are constraints to the use of vaccines as a 
cheap public health tool since they result in more bulk, leading to costs of shipping and 
transportation to hard-to-reach areas in developing country settings. We compared the 
safety and immunogenic profile of different formulations of Dukoral. When Dukoral was 
reconstituted in water or given without any additional fluid, the safety profile remained 
unchanged and the vibriocidal responses were comparable with those obtained with 
standard buffer formulation. However, in the 10-18 months old children, two doses of the 
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vaccine gave significantly higher antitoxin responses when using standard buffer 
formulation as compared to when using water or not adding any fluids, whereas there was 
no difference in the antitoxin responses in the youngest, 6-9 month old children when 
using buffer or water. These findings suggest that Dukoral may be given with water to 
young children <10 months to avoid bulk supply and to reduce shipment costs, whereas 
an acid neutralizing buffer is required to retain the immunogenicity of the CTB 
component in children >10 months.  
 
We also evaluated different strategies to further improve the immunogenicity of Dukoral. 
One of the factors that has been suggested to be related to hyporesponsiveness of 
vaccines in developing countries is frequent intake of breast milk, which may inhibit 
vaccine take rates (24, 132, 176). Our studies show that the vibriocidal antibody 
responses were increased when breast-feeding was temporarily withheld for 3 hours prior 
to immunization. This effect was only seen in children 10-18 month of age and not in 
younger infants. This may be due to that breast milk remains for a longer time in the 
intestine of the younger children due to slower gastric emptying (23) and hence 
withholding breast feeding for 3 hours may not be sufficient in very young children.  
 
We found that about 50% of the children participating in our studies were zinc deficient. 
Previous studies have shown that zinc is required for normal T-cell function and zinc 
deficiency has been shown to be associated with decreased vaccine specific T-cell and 
antibody responses as well as memory responses (36, 43, 44, 113). However, the 
mechanisms responsible for the positive effects of zinc treatment observed after 
vaccination as well as in different infections have not been elucidated. Furthermore, it is 
still unclear if zinc only promotes immune responses in zinc deficient individuals. Our 
studies of the influence of zinc supplementation on B- and T-cell responses to the cholera 
vaccine in young children in Bangladesh showed that zinc supplementation can enhance 
the vibriocidal antibody responses to the oral cholera vaccine, but only in older children 
10-18 month of age. We also revealed that the IFN- responses after stimulation with a 
modified CTB molecule were significantly stronger in vaccinated children receiving zinc 
supplementation compared to children who received only vaccine. In contrast, no 
influence of zinc was observed on the T-cell proliferative responses to CTB. Previous 
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studies indicate that zinc supplementation can promote both proliferative and cytokine 
responses in T cells (1, 38, 43, 112, 113), and it is unclear at present why zinc 
supplementation only influenced the IFN- responses in our study.  
 
We also analyzed if zinc sufficient and deficient children responded differently to the 
vaccine after having been supplemented with the micronutrient. We observed that zinc 
supplementation enhanced the vibriocidal antibody responses in the zinc deficient 
children more than in those children who were not deficient at onset of vaccination. 
However, this is in contrast to observations in zinc sufficient adults in Norway, who 
responded with significantly higher vibriocidal antibody responses after zinc 
supplementation than those given vaccine without zinc (77).  
 
In contrast to the B-cell responses, we did not see any difference in the T-cell responses 
between children with different baseline zinc status.  This may suggest that T cells and B 
cells have different requirements for zinc for optimal function but need to be confirmed 
in a lager study. It has been speculated that supplementation with zinc during vaccination 
may hinder efficient vaccination responses in children who are zinc sufficient already 
before zinc supplementation (101, 108) and suppressive effects on antitoxic antibody 
responses by zinc have been observed in studies in older children and adults (77, 118). 
However, we did not observe any tendency for zinc to suppress either antibody or T-cell 
responses in any of the study groups. Our data thus support that zinc may be given to 
children older than 9 months of age, since this is the age group, who are the most at risk 
of micronutrient deficiency and who may need supplementation to improve vaccine take 
rates.  
 
Changing patterns of ETEC CFs are now apparent worldwide. CS6 has during recent 
years emerged as one of the major CFs, e.g. in Mexico, Guatemala, Egypt and 
Bangladesh (138, 139, 146, 187), making it a key component to be included in an 
effective ETEC vaccine. Based on disappointing immune responses to CS6 in different 
candidate vaccines during recent years (19, 34, 42, 56, 79, 180, 189), we wanted to 
elucidate the immunogenicity of this CF after clinical infections with CS6 expressing 
ETEC bacteria. This was done by determining the systemic and mucosal antibody 
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responses to CS6 in patients hospitalized due to diarrhea caused by CS6 positive ETEC. 
The results of these analyses showed that by early convalescence, most patients 
responded with significantly increased levels of IgA and IgG antibodies in serum. 
Similarly, ASC, ALS and fecal IgA responses to CS6 were found in a majority of the 
patients, supporting the mucosal immunogenicity of CS6.  
 
Thus, since natural infection with CS6 positive ETEC induces comparatively strong 
mucosal as well as systemic immune responses, inducing of protective immune response 
to CS6 using suitable candidate vaccines and immunization regimens may be feasible. 
Studies are in progress to construct E. coli bacteria overexpressing CS6 as candidate 
vaccine strains (170), since clinical ETEC isolates express comparatively low levels of 
this non-fimbrial CF.  
 
To determine genetic influences on the susceptibility to ETEC infections with major CFs 
and toxins, we have investigated the relationship between blood group phenotypes and 
incidence of symptomatic and asymptomatic ETEC infections in a cohort of children in 
Bangladesh, who were followed from the day of birth (127). In initial studies, we found 
that blood group A children in this cohort were more susceptible to ETEC diarrhea than 
children with other blood groups (127). We have now also analyzed if there is a relation 
between Lewis blood groups and ETEC diseases. The distribution of Lewis blood group 
phenotypes of Bangladeshi participants was found to be similar to the Lewis antigen 
distribution in Indian and African populations (11, 22, 33, 109). However, an interesting 
observation was that the distribution of Lewis (a+b-) phenotype in Bangladeshi children 
and adults is higher than that seen in developed countries and this could certainly have 
implications for susceptibility to infections and vaccine interventions as well. Thus, in 
this study we show that children with Le (a+b-) phenotype had significantly higher 
incidence of diarrhea caused by ETEC expressing CFA/I group than children in the Le (a-
b+) group. This may be related to the recently reported capacity of E. coli expressing 
CFA/I-, CS1- or CS4-fimbriae to bind to Lea-terminated glycosphingolipids, while Leb-
terminated glycosphingolipids are not recognized by these CFs (67). Thus, the present 
findings support that ETEC bacteria expressing the CFA/I group fimbriae, i.e. CFA/I and 
related CFs, may bind to Lea determinants expressed by intestinal epithelial cells. ETEC 
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strains expressing CS6 were not associated with the Lewis blood group phenotype. This 
is also supported by a recent study showing that that CS6 antigen does not bind to any 
type of Lewis blood group determinants, but instead to sulfatide (SO3-3-β1 
galactosylceramide) (66) confirming the present clinical data. Thus, the blood group 
phenotype of the host might have important influences on the susceptibility to different 
types of ETEC in different populations, and the high prevalence of the Le (a+b-) 
phenotype in Bangladesh suggests that a vaccine, which provides protection against 
CFA/I group expressing ETEC, is particularly important in this population. 
 
Overall, our results reveal that both a reduced dose of the ETEC vaccine and a full dose 
of Dukoral is safe and immunogenic in infants and young children in developing 
countries. Interventions, including use of zinc and brief intermission of breast-feeding, 
were shown to further enhance the immunogenicity of Dukoral and will be tested alone 
and in combination for the capacity to enhance immune responses to other oral vaccines, 
including ETEC vaccines, in the near future. Our data also suggest that incorporation of 
the CS6 antigen should be beneficial for a new generation of ETEC vaccines, since this 
antigen can induce robust immune response in both children and adults. Finally, a genetic 
preponderance of Lewis (a+b-) positive individuals for ETEC diarrhea caused by bacteria 
expressing CFA/I group fimbriae has been identified. In conclusion, the results of this 
study are encouraging for the potential use of enteric vaccines in young children in 
endemic areas, who need such vaccines urgently. 
 
Based on the results of these studies, we recommend that different interventions should 
be utilized to provide maximal efficacy of different oral vaccines in young children in 
developing countries. Before going to large scale trials, dosing studies should be 
performed to avoid adverse reactions but still induce strong immune responses. Different 
simple interventions that may improve vaccine efficacy, such as temporary withholding 
of breast milk, should also be evaluated. Identification of proper antigens as well as 
possibilities to lower the number of bacteria with higher expression of protective antigens 
should also be considered. Timing of vaccination should also be chosen to avoid 
vaccination during seasonal epidemic periods. In addition, environmental factors such as 
arsenic toxicity, which is a common problem in Bangladesh due to poor drinking water 
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quality, malnutrition and helminthic and parasitic load of the host (138), interaction with 
vaccines used in the expanded program for immunization, booster dosing, and putative 
adjuvants, etc that may influence vaccine immunogenicity, should be considered to 
identify optimal vaccination strategies in developing country settings.  
  ‐ 60 ‐
ACKNOWLEDGEMENTS 
This thesis arose as a result of years of research that I have done within collaborative 
studies between the ICDDR,B and the University of Gothenburg. During these years, I 
have worked with a great number of people whose contribution in assorted ways to the 
research and the making of this thesis deserve to be specially mentioned. It is a pleasure 
to convey my gratitude to them all in my humble acknowledgment. 
 
In the first place I would like to record my gratitude to my main supervisors, Ann-Mari 
Svennerholm and Anna Lundgren at the University of Gothenburg, for their 
supervision, advice, and guidance from the very early stage of this research as well as 
giving me extraordinary experiences through out the work. Above all and the most 
needed, they provided me persistent encouragement and support in various ways. 
Throughout my thesis-writing period, I have particularly benefited from Anna, who 
provided constant encouragement, sound advice, good teaching, good company, and lots 
of good ideas. Their truly scientist intuition has exceptionally inspired and enriched my 
growth as a student, a researcher and a scientist want to be. I am indebted to them more 
than they know. 
 
It is difficult to overstate my gratitude to my co-supervisor, Firdausi Qadri (Apa) at the 
ICDDR,B in Dhaka. With her enthusiasm, her inspiration, and her great efforts to explain 
things clearly and simply, she helped to make research fun for me. Her involvement with 
her originality has triggered and nourished my intellectual maturity that I will benefit 
from, for a long time to come. I gratefully acknowledge Apa for her advice, supervision, 
and crucial contribution throughout my research and thesis writing periods. I would have 
been lost without her. Apa, I am grateful in every possible way and hope to keep up our 
teamwork in the future. 
 
I convey special acknowledgement to Alejandro Cravioto, Executive Director of 
ICDDR,B, for his indispensable help for approving my PhD funds, so I could optimally 
carry out my studies at the University of Gothenburg.  
 
I was extraordinarily fortunate in having Susann Teneberg as a collaborator at the 
University of Gothenburg. I could never have embarked on the Lewis blood group work 
without her vast knowledge of biochemical binding of Lewis blood group antigens and 
her help thus opened up unknown areas to me. Thank you. 
 
It is a pleasure to express my gratitude wholeheartedly to Jan Holmgren for his scientific 
inputs and kind hospitality while I was staying with my family in Gothenburg. 
 
I gratefully thank Amit Saha and Mohiul Chowdhury for their vital support in 
recruiting and overseeing the studies at the field site in Mirpur. Without their active 
support, all the research activities had been impossible to accomplish. I would also like to 
thank all the field staff and study participants who were involved in this research.  
 
My special thanks go to Mohmmad Arifuzzaman, without his tremendous work on the 
FASCIA and Lewis blood group detection methods would have been unthinkable. 
Furthermore, I would particularly like to thank my colleagues Taufiqur Bhuiyan, 
Abdullah Tarique, Atiqur Rahman and Sajib Chakraborty, who were helping me at 
the Lab, whenever I needed them. My thanks also go to all the other lab colleagues at the 
  ‐ 61 ‐
ICDDR,B, who has done a great job for helping to do all the ELISA and vibriocidal 
assays. I would also like to thank Joanna Kaim, who helped to set up the FASCIA 
method in Gothenburg. 
 
Collective and individual acknowledgments are also owed to my colleagues and co-
authors of my papers at the ICDDR,B, University of Gothenburg and elsewhere in the 
world. Many thanks go in particular to Yasmin Begum, Firoz Ahmed, David Sack, 
Endtz Hubert, Michael Lebens, Nils Lycke, Samuel Lundin, Sanna Cardell, Simin 
Meydani, Dayong Wu, Daniel Novak, Hanna Stenstad, Sara Tengvall, Sukanya 
Raghavan, Ǻsa Sjöling, Ali Harandi, Joshua Tobias, Marianne Quiding, Paul Bland, 
Ingrid Bölin and Nadir Kadir for giving me such a pleasant time when working 
together.  
 
Many thanks go to my many student colleagues in Gothenburg for providing a 
stimulating and fun environment in which to learn and grow. I am especially grateful to 
Patrik Sundström, Reza, Mamun, Bert Kindlund, Erik Nygren, Claudia Rodas, Ǻsa 
Lothigius, Veronica Olofsson, Susannah Leach and Anders Janzon.  
 
I gratefully thank Faozul Kabir, Susanne Uhlan, Andrea Frateschi, Annika Djärf, 
Tinna Carlsson and Gudrun Wiklund for their indispensable help dealing with travel 
arrangement, office supplies, administration, shipments and bureaucratic matters during 
my stay and my commuting between Dhaka and Gothenburg. 
 
I wish to thank my entire extended family for providing a loving environment for me. My 
parents deserve special mention for their inseparable support and prayers. My Late 
Father, Amjad Hossain and my Mother, Fahmida Hossain, are those who sincerely 
raised me with their caring and gently love. Dulabhai (Bulbul), Apa (Ivy), Taposh 
Bhai, Apee (Iris), Zaman, Farhana, Monty, Mumu, Babu Bhai, Bakul Bhabi, Babul 
Bhai, Shishir Apu, Dipto, Mohua, Parash, Barna, Niloy, Onindo, Naveel, Naveed 
and Rahul, thanks for being as supportive and caring family members. Words fail me to 
express my appreciation to my wife Chuty whose dedication, love and persistent 
confidence in me, has taken the load off my shoulder. I owe her for being unselfishly let 
her intelligence, passions, and ambitions collide with mine. Therefore, I would also thank 
Bazlur and Lutfa Rahman’s family for letting me take her hand in marriage, and 
accepting me as a member of the family, warmly. And most importantly, my thanks to 
my daughters, Ariana and Tanisha for giving me happiness and joy.  
 
Finally, I would like to thank everybody who was important to the successful realization 
of this thesis, as well as expressing my apology that I could not mention all of you 
personally one by one. 
 
 
 
 
This work was supported by grants from the Swedish Agency for International 
Development and Corporation (Sida-SAREC), the Marianne and Markus Wallenberg 
Foundation through the support to GUVAX, the Swedish Medical Research Council, the 
Sahlgrenska Academy of the University of Gothenburg, and the International Centre for 
Diarrhoeal Disease Research, Bangladesh (ICDDR,B). 
  ‐ 62 ‐
REFERENCES 
1. Achiron, A., M. Gurevich, Y. Snir, E. Segal, and M. Mandel. 2007. Zinc-ion 
binding and cytokine activity regulation pathways predicts outcome in relapsing-
remitting multiple sclerosis. Clinical and experimental immunology 149:235-242. 
2. Ahren, C., M. Jertborn, and A. M. Svennerholm. 1998. Intestinal immune 
responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and 
associated immunoglobulin A responses in blood. Infection and immunity 
66:3311-3316. 
3. Ahren, C. M., and A. M. Svennerholm. 1982. Synergistic protective effect of 
antibodies against Escherichia coli enterotoxin and colonization factor antigens. 
Infection and immunity 38:74-79. 
4. Albert, M. J., F. Qadri, M. A. Wahed, T. Ahmed, A. S. Rahman, F. Ahmed, 
N. A. Bhuiyan, K. Zaman, A. H. Baqui, J. D. Clemens, and R. E. Black. 2003. 
Supplementation with zinc, but not vitamin A, improves seroconversion to 
vibriocidal antibody in children given an oral cholera vaccine. The Journal of 
infectious diseases 187:909-913. 
5. Ali, M., M. Emch, L. von Seidlein, M. Yunus, D. A. Sack, M. Rao, J. 
Holmgren, and J. D. Clemens. 2005. Herd immunity conferred by killed oral 
cholera vaccines in Bangladesh: a reanalysis. Lancet 366:44-49. 
6. Ali, M., M. Emch, M. Yunus, D. Sack, A. L. Lopez, J. Holmgren, and J. 
Clemens. 2008. Vaccine Protection of Bangladeshi infants and young children 
against cholera: implications for vaccine deployment and person-to-person 
transmission. The Pediatric infectious disease journal 27:33-37. 
7. Anantha, R. P., A. L. McVeigh, L. H. Lee, M. K. Agnew, F. J. Cassels, D. A. 
Scott, T. S. Whittam, and S. J. Savarino. 2004. Evolutionary and functional 
relationships of colonization factor antigen I and other class 5 adhesive fimbriae 
of enterotoxigenic Escherichia coli. Infection and immunity 72:7190-7201. 
8. Asaduzzaman, M., E. T. Ryan, M. John, L. Hang, A. I. Khan, A. S. Faruque, 
R. K. Taylor, S. B. Calderwood, and F. Qadri. 2004. The major subunit of the 
toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A 
immune responses in patients with cholera caused by Vibrio cholerae O1 and 
O139. Infection and immunity 72:4448-4454. 
9. Attridge, S. R., P. A. Manning, J. Holmgren, and G. Jonson. 1996. Relative 
significance of mannose-sensitive hemagglutinin and toxin-coregulated pili in 
colonization of infant mice by Vibrio cholerae El Tor. Infection and immunity 
64:3369-3373. 
10. Baqui, A. H., R. E. Black, R. B. Sack, H. R. Chowdhury, M. Yunus, and A. 
K. Siddique. 1993. Malnutrition, cell-mediated immune deficiency, and diarrhea: 
a community-based longitudinal study in rural Bangladeshi children. American 
journal of epidemiology 137:355-365. 
11. Bhatia, H. M. 1965. Occurrence of Lewis antibodies in Bombay. The Indian 
journal of medical research 53:972-974. 
12. Bjork, S., M. E. Breimer, G. C. Hansson, K. A. Karlsson, and H. Leffler. 
1987. Structures of blood group glycosphingolipids of human small intestine. A 
relation between the expression of fucolipids of epithelial cells and the ABO, Le 
and Se phenotype of the donor. Journal of biological chemistry 262:6758-6765. 
  ‐ 63 ‐
13. Black, R. E. 1993. Epidemiology of diarrhoeal disease: implications for control 
by vaccines. Vaccine 11:100-106. 
14. Black, R. E. 1990. Epidemiology of travelers' diarrhea and relative importance of 
various pathogens. Reviews of infectious diseases 12 Suppl 1:S73-79. 
15. Black, R. E. 1993. Persistent diarrhea in children of developing countries. The 
Pediatric infectious disease journal 12:751-761; discussion 762-754. 
16. Black, R. E., K. H. Brown, and S. Becker. 1984. Effects of diarrhea associated 
with specific enteropathogens on the growth of children in rural Bangladesh. 
Pediatrics 73:799-805. 
17. Boren, T., P. Falk, K. A. Roth, G. Larson, and S. Normark. 1993. Attachment 
of Helicobacter pylori to human gastric epithelium mediated by blood group 
antigens. Science 262:1892-1895. 
18. Boren, T., S. Normark, and P. Falk. 1994. Helicobacter pylori: molecular basis 
for host recognition and bacterial adherence. Trends in microbiology 2:221-228. 
19. Byrd, W., and F. J. Cassels. 2006. Intranasal immunization of BALB/c mice 
with enterotoxigenic Escherichia coli colonization factor CS6 encapsulated in 
biodegradable poly(DL-lactide-co-glycolide) microspheres. Vaccine 24:1359-
1366. 
20. Carpenter, C. M., E. R. Hall, R. Randall, R. McKenzie, F. Cassels, N. Diaz, 
N. Thomas, P. Bedford, M. Darsley, C. Gewert, C. Howard, R. B. Sack, D. A. 
Sack, H. S. Chang, G. Gomes, and A. L. Bourgeois. 2006. Comparison of the 
antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of 
mucosal immune responses to antigens of enterotoxigenic Escherichia coli in 
challenged and vaccinated volunteers. Vaccine 24:3709-3718. 
21. Castello-Branco, L. R., G. E. Griffin, T. A. Poulton, G. Dougan, and D. J. 
Lewis. 1994. Characterization of the circulating T-cell response after oral 
immunization of human volunteers with cholera toxin B subunit. Vaccine 12:65-
72. 
22. Chakraborty, R., S. K. Das, and M. Roy. 1975. Blood group genetics of some 
caste groups of Southern 24 Parganas, West Bengal. Human heredity 25:218-225. 
23. Clemens, J. D., M. Jertborn, D. Sack, B. Stanton, J. Holmgren, M. R. Khan, 
and S. Huda. 1986. Effect of neutralization of gastric acid on immune responses 
to an oral B subunit, killed whole-cell cholera vaccine. The Journal of infectious 
diseases 154:175-178. 
24. Clemens, J. D., D. A. Sack, J. Chakraborty, M. R. Rao, F. Ahmed, J. R. 
Harris, F. van Loon, M. R. Khan, M. Yunis, S. Huda, and et al. 1990. Field 
trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-
toxic breast-milk immunity in response to ingestion of the vaccines. Vaccine 
8:469-472. 
25. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, M. R. Khan, S. 
Huda, F. Ahmed, J. Gomes, M. R. Rao, A. M. Svennerholm, and et al. 1989. 
ABO blood groups and cholera: new observations on specificity of risk and 
modification of vaccine efficacy. The Journal of infectious diseases 159:770-773. 
26. Clemens, J. D., D. A. Sack, J. R. Harris, F. Van Loon, J. Chakraborty, F. 
Ahmed, M. R. Rao, M. R. Khan, M. Yunus, N. Huda, and et al. 1990. Field 
  ‐ 64 ‐
trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. 
Lancet 335:270-273. 
27. Clemens, J. D., B. F. Stanton, J. Chakraborty, D. A. Sack, M. R. Khan, S. 
Huda, F. Ahmed, J. R. Harris, M. Yunus, M. U. Khan, and et al. 1987. B 
subunit-whole cell and whole cell-only oral vaccines against cholera: studies on 
reactogenicity and immunogenicity. The Journal of infectious diseases 155:79-85. 
28. Concha, A., A. Giraldo, E. Castaneda, M. Martinez, F. de la Hoz, F. Rivas, A. 
Depetris, A. M. Svennerholm, and D. A. Sack. 1995. Safety and 
immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine 
in Barranquilla, Colombia. Bulletin of the Pan American Health Organization 
29:312-321. 
29. Cryz, S. J., Jr., J. Kaper, C. Tacket, J. Nataro, and M. M. Levine. 1995. 
Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, 
immunogenicity, excretion and non-target effects. Developments in biological 
standardization 84:237-244. 
30. Cryz, S. J., Jr., M. M. Levine, G. Losonsky, J. B. Kaper, and B. Althaus. 
1992. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-
HgR live oral cholera vaccine in Swiss adults. Infection and immunity 60:3916-
3917. 
31. Czerkinsky, C., Z. Moldoveanu, J. Mestecky, L. A. Nilsson, and O. 
Ouchterlony. 1988. A novel two colour ELISPOT assay. I. Simultaneous 
detection of distinct types of antibody-secreting cells. Journal of immunological 
methods 115:31-37. 
32. Czerkinsky, C., A. M. Svennerholm, M. Quiding, R. Jonsson, and J. 
Holmgren. 1991. Antibody-producing cells in peripheral blood and salivary 
glands after oral cholera vaccination of humans. Infection and immunity 59:996-
1001. 
33. Daniels, G. 1995. ABO, Hh and Lewis systems, p. 7-67. Human Blood Groups. 
Blackwell Science. 
34. de Lorimier, A. J., W. Byrd, E. R. Hall, W. M. Vaughan, Tang D, Z. J. 
Roberts, C. E. McQueen, and F. J. Cassels. 2003. Murine antibody response to 
intranasally administered enterotoxigenic Escherichia coli colonization factor 
CS6. Vaccine 21:2548–2555. 
35. Deen, J. L., L. von Seidlein, D. Sur, M. Agtini, M. E. Lucas, A. L. Lopez, D. 
R. Kim, M. Ali, and J. D. Clemens. 2008. The high burden of cholera in 
children: comparison of incidence from endemic areas in Asia and Africa. PLoS 
neglected tropical diseases 2:e173. 
36. DePasquale-Jardieu, P., and P. J. Fraker. 1984. Interference in the 
development of a secondary immune response in mice by zinc deprivation: 
persistence of effects. The Journal of nutrition 114:1762-1769. 
37. Domok, I., M. S. Balayan, O. A. Fayinka, N. Skrtic, A. D. Soneji, and P. S. 
Harland. 1974. Factors affecting the efficacy of live poliovirus vaccine in warm 
climates. Efficacy of type 1 Sabin vaccine administered together with antihuman 
gamma-globulin horse serum to breast-fed and artificially fed infants in Uganda. 
Bulletin of the World Health Organization 51:333-347. 
  ‐ 65 ‐
38. Duchateau, J., G. Delespesse, and P. Vereecke. 1981. Influence of oral zinc 
supplementation on the lymphocyte response to mitogens of normal subjects. 
American journal of clinical nutrition 34:88-93. 
39. Elson, C. O., and W. Ealding. 1984. Generalized systemic and mucosal 
immunity in mice after mucosal stimulation with cholera toxin. The Journal of 
Immunology 132:2736-2741. 
40. Evans, D. G., D. J. Evans, Jr., S. Clegg, and J. A. Pauley. 1979. Purification 
and characterization of the CFA/I antigen of enterotoxigenic Escherichia coli. 
Infection and immunity 25:738-748. 
41. Evans, D. G., D. J. Evans, Jr., A. R. Opekun, and D. Y. Graham. 1988. Non-
replicating oral whole cell vaccine protective against enterotoxigenic Escherichia 
coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-
LT) intestinal IgA and protection against challenge with ETEC belonging to 
heterologous serotypes. FEMS microbiology immunology 1:117-125. 
42. Favre, D., S. Ludi, M. Stoffel, J. Frey, M. P. Horn, G. Dietrich, S. Spreng, 
and J. F. Viret. 2006. Expression of enterotoxigenic Escherichia coli 
colonization factors in Vibrio cholerae. Vaccine 24:4354-4368. 
43. Fraker, P. J., M. E. Gershwin, R. A. Good, and A. Prasad. 1986. 
Interrelationships between zinc and immune function. Federation proceedings 
45:1474-1479. 
44. Fraker, P. J., P. Jardieu, and J. Cook. 1987. Zinc deficiency and immune 
function. Archives of dermatology 123:1699-1701. 
45. Gaastra, W., and F. K. de Graaf. 1982. Host-specific fimbrial adhesins of 
noninvasive enterotoxigenic Escherichia coli strains. Microbiological reviews 
46:129-161. 
46. Gaastra, W., and A. M. Svennerholm. 1996. Colonization factors of human 
enterotoxigenic Escherichia coli (ETEC). Trends in microbiology 4:444-452. 
47. Gans, H. A., A. M. Arvin, J. Galinus, L. Logan, R. DeHovitz, and Y. 
Maldonado. 1998. Deficiency of the humoral immune response to measles 
vaccine in infants immunized at age 6 months. Jama 280:527-532. 
48. Garcia, L., M. D. Jidy, H. Garcia, B. L. Rodriguez, R. Fernandez, G. Ano, B. 
Cedre, T. Valmaseda, E. Suzarte, M. Ramirez, Y. Pino, J. Campos, J. 
Menendez, R. Valera, D. Gonzalez, I. Gonzalez, O. Perez, T. Serrano, M. 
Lastre, F. Miralles, J. Del Campo, J. L. Maestre, J. L. Perez, A. Talavera, A. 
Perez, K. Marrero, T. Ledon, and R. Fando. 2005. The vaccine candidate 
Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infection 
and immunity 73:3018-3024. 
49. Gibson, R. S., S. Y. Hess, C. Hotz, and K. H. Brown. 2008. Indicators of zinc 
status at the population level: a review of the evidence. The British journal of 
nutrition 99 Suppl 3:S14-23. 
50. Gill, D. M. 1976. The arrangement of subunits in cholera toxin. Biochemistry 
15:1242-1248. 
51. Glass, R. I., J. Holmgren, C. E. Haley, M. R. Khan, A. M. Svennerholm, B. J. 
Stoll, K. M. Belayet Hossain, R. E. Black, M. Yunus, and D. Barua. 1985. 
Predisposition for cholera of individuals with O blood group. Possible 
evolutionary significance. American journal of epidemiology 121:791-796. 
  ‐ 66 ‐
52. Glass, R. I., and B. J. Stoll. 1989. The protective effect of human milk against 
diarrhea. A review of studies from Bangladesh. Acta paediatrica Scandinavica 
Suppl 351:131-136. 
53. Glass, R. I., B. J. Stoll, R. G. Wyatt, Y. Hoshino, H. Banu, and A. Z. 
Kapikian. 1986. Observations questioning a protective role for breast-feeding in 
severe rotavirus diarrhea. Acta paediatrica Scandinavica 75:713-718. 
54. Gomez, H. F., I. Herrera-Insua, M. M. Siddiqui, V. A. Diaz-Gonzalez, E. 
Caceres, D. S. Newburg, and T. G. Cleary. 2001. Protective role of human 
lactoferrin against invasion of Shigella flexneri M90T. Advances in experimental 
medicine and biology 501:457-467. 
55. Gotuzzo, E., B. Butron, C. Seas, M. Penny, R. Ruiz, G. Losonsky, C. F. 
Lanata, S. S. Wasserman, E. Salazar, J. B. Kaper, and et al. 1993. Safety, 
immunogenicity, and excretion pattern of single-dose live oral cholera vaccine 
CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. 
Infection and immunity 61:3994-3997. 
56. Guerena-Burgueno, F., E. R. Hall, D. N. Taylor, F. J. Cassels, D. A. Scott, M. 
K. Wolf, Z. J. Roberts, G. V. Nesterova, C. R. Alving, and G. M. Glenn. 2002. 
Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli 
vaccine administered transcutaneously. Infection and immunity 70:1874-1880. 
57. Hall, E. R., T. F. Wierzba, C. Ahren, M. R. Rao, S. Bassily, W. Francis, F. Y. 
Girgis, M. Safwat, Y. J. Lee, A. M. Svennerholm, J. D. Clemens, and S. J. 
Savarino. 2001. Induction of systemic antifimbria and antitoxin antibody 
responses in Egyptian children and adults by an oral, killed enterotoxigenic 
Escherichia coli plus cholera toxin B subunit vaccine. Infection and immunity 
69:2853-2857. 
58. Haque, R., D. Mondal, B. D. Kirkpatrick, S. Akther, B. M. Farr, R. B. Sack, 
and W. A. Petri, Jr. 2003. Epidemiologic and clinical characteristics of acute 
diarrhea with emphasis on Entamoeba histolytica infections in preschool children 
in an urban slum of Dhaka, Bangladesh. American journal of tropical medicine 
and hygiene 69:398-405. 
59. Harris, A. M., F. Chowdhury, Y. A. Begum, A. I. Khan, A. S. Faruque, A. M. 
Svennerholm, J. B. Harris, E. T. Ryan, A. Cravioto, S. B. Calderwood, and F. 
Qadri. 2008. Shifting prevalence of major diarrheal pathogens in patients seeking 
hospital care during floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. 
American journal of tropical medicine and hygiene 79:708-714. 
60. Harris, J. B., A. I. Khan, R. C. LaRocque, D. J. Dorer, F. Chowdhury, A. S. 
Faruque, D. A. Sack, E. T. Ryan, F. Qadri, and S. B. Calderwood. 2005. 
Blood group, immunity, and risk of infection with Vibrio cholerae in an area of 
endemicity. Infection and immunity 73:7422-7427. 
61. Helander, A., G. C. Hansson, and A. M. Svennerholm. 1997. Binding of 
enterotoxigenic Escherichia coli to isolated enterocytes and intestinal mucus. 
Microbial pathogenesis 23:335-346. 
62. Helander, A., G. C. Hansson, and A. M. Svennerholm. 1997. Binding of 
human enterotoxigenic Escherichia coli expressing coli surface antigen 6 to rabbit 
intestinal enterocytes and glycoproteins. Advances in experimental medicine and 
biology 412:257-258. 
  ‐ 67 ‐
63. Helander, A., C. Wenneras, F. Qadri, and A. M. Svennerholm. 1998. 
Antibody responses in humans against coli surface antigen 6 of enterotoxigenic 
Escherichia coli. Infection and immunity 66:4507-4510. 
64. Henry, S., R. Oriol, and B. Samuelsson. 1995. Lewis histo-blood group system 
and associated secretory phenotypes. Vox sanguinis 69:166-182. 
65. Ikehara, Y., S. Nishihara, H. Yasutomi, T. Kitamura, K. Matsuo, N. Shimizu, 
K. Inada, Y. Kodera, Y. Yamamura, H. Narimatsu, N. Hamajima, and M. 
Tatematsu. 2001. Polymorphisms of two fucosyltransferase genes (Lewis and 
Secretor genes) involving type I Lewis antigens are associated with the presence 
of anti-Helicobacter pylori IgG antibody. Cancer epidemiology biomarkers & 
prevention 10:971-977. 
66. Jansson, L., J. Tobias, C. Jarefjall, M. Lebens, A. M. Svennerholm, and S. 
Teneberg. 2009. Sulfatide recognition by colonization factor antigen CS6 from 
enterotoxigenic Escherichia coli. PLoS ONE 4:e4487. 
67. Jansson, L., J. Tobias, M. Lebens, A. M. Svennerholm, and S. Teneberg. 
2006. The major subunit, CfaB, of colonization factor antigen i from 
enterotoxigenic Escherichia coli is a glycosphingolipid binding protein. Infection 
and immunity 74:3488-3497. 
68. Jertborn, M., C. Ahren, J. Holmgren, and A. M. Svennerholm. 1998. Safety 
and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli 
vaccine. Vaccine 16:255-260. 
69. Jertborn, M., C. Ahren, and A. M. Svennerholm. 2001. Dose-dependent 
circulating immunoglobulin A antibody-secreting cell and serum antibody 
responses in Swedish volunteers to an oral inactivated enterotoxigenic 
Escherichia coli vaccine. Clinical and diagnostic laboratory immunology 8:424-
428. 
70. Jertborn, M., A. M. Svennerholm, and J. Holmgren. 1996. Intestinal and 
systemic immune responses in humans after oral immunization with a bivalent B 
subunit-O1/O139 whole cell cholera vaccine. Vaccine 14:1459-1465. 
71. Jertborn, M., A. M. Svennerholm, and J. Holmgren. 1992. Safety and 
immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in 
Swedish volunteers. Vaccine 10:130-132. 
72. Jertborn, M., A. M. Svennerholm, and J. Holmgren. 1986. Saliva, breast milk, 
and serum antibody responses as indirect measures of intestinal immunity after 
oral cholera vaccination or natural disease. Journal of clinical microbiology 
24:203-209. 
73. Jiang, Z. D., D. Greenberg, J. P. Nataro, R. Steffen, and H. L. DuPont. 2002. 
Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli 
virulence factors in international travelers. Journal of clinical microbiology 
40:4185-4190. 
74. Jobling, M. G., and R. K. Holmes. 1991. Analysis of structure and function of 
the B subunit of cholera toxin by the use of site-directed mutagenesis. Molecular 
microbiology 5:1755-1767. 
75. John, T. J. 2004. A developing country perspective on vaccine-associated 
paralytic poliomyelitis. Bulletin of the World Health Organization 82:53-57; 
discussion 57-58. 
  ‐ 68 ‐
76. Jonson, G., J. Sanchez, and A. M. Svennerholm. 1989. Expression and 
detection of different biotype-associated cell-bound haemagglutinins of Vibrio 
cholerae O1. Journal of general microbiology 135:111-120. 
77. Karlsen, T. H., H. Sommerfelt, S. Klomstad, P. K. Andersen, T. A. Strand, R. 
J. Ulvik, C. Ahren, and H. M. Grewal. 2003. Intestinal and systemic immune 
responses to an oral cholera toxoid B subunit whole-cell vaccine administered 
during zinc supplementation. Infection and immunity 71:3909-3913. 
78. Karlsson, K. A., and G. Larson. 1981. Potential use of glycosphingolipids of 
human meconium for blood group chemotyping of single individuals. FEBS 
letters 128:71-74. 
79. Katz, D. E., A. J. DeLorimier, M. K. Wolf, E. R. Hall, F. J. Cassels, J. E. van 
Hamont, R. L. Newcomer, M. A. Davachi, D. N. Taylor, and C. E. McQueen. 
2003. Oral immunization of adult volunteers with microencapsulated 
enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 21:341-346. 
80. Kenner, J. R., T. S. Coster, D. N. Taylor, A. F. Trofa, M. Barrera-Oro, T. 
Hyman, J. M. Adams, D. T. Beattie, K. P. Killeen, D. R. Spriggs, and et al. 
1995. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio 
cholerae O1. The Journal of infectious diseases 172:1126-1129. 
81. Kotloff, K. L., S. S. Wasserman, S. O'Donnell, G. A. Losonsky, S. J. Cryz, 
and M. M. Levine. 1992. Safety and immunogenicity in North Americans of a 
single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, 
placebo-controlled, double-blind crossover trial. Infection and immunity 60:4430-
4432. 
82. Larson, G., L. Svensson, L. Hynsjo, A. Elmgren, and L. Rydberg. 1999. 
Typing for the human lewis blood group system by quantitative fluorescence-
activated flow cytometry: large differences in antigen presentation on 
erythrocytes between A(1), A(2), B, O phenotypes. Vox sanguinis 77:227-236. 
83. Lawler, S. D., and R. Marshall. 1961. Lewis and secretor characters in infancy. 
Vox Sang 6:541-554. 
84. Lebens, M., S. Johansson, J. Osek, M. Lindblad, and J. Holmgren. 1993. 
Large-scale production of Vibrio cholerae toxin B subunit for use in oral 
vaccines. Bio/technology (Nature Publishing Company) 11:1574-1578. 
85. Legros, D., C. Paquet, W. Perea, I. Marty, N. K. Mugisha, H. Royer, M. 
Neira, and B. Ivanoff. 1999. Mass vaccination with a two-dose oral cholera 
vaccine in a refugee camp. Bulletin of the World Health Organization 77:837-
842. 
86. Levine, M. M., D. R. Nalin, D. L. Hoover, E. J. Bergquist, R. B. Hornick, and 
C. R. Young. 1979. Immunity to enterotoxigenic Escherichia coli. Infection and 
immunity 23:729-736. 
87. Lewis, D. J., L. R. Castello-Branco, P. Novotny, G. Dougan, T. A. Poulton, 
and G. E. Griffin. 1993. Circulating cellular immune response to oral 
immunization of humans with cholera toxin B-subunit. Vaccine 11:119-121. 
88. Limas, C. 1991. Quantitative interrelations of Lewis antigens in normal mucosa 
and transitional cell bladder carcinomas. Journal of clinical pathology 44:983-
989. 
  ‐ 69 ‐
89. Linhares, A. C., K. B. Carmo, K. K. Oliveira, C. S. Oliveira, R. B. Freitas, N. 
Bellesi, T. A. Monteiro, Y. B. Gabbay, and J. D. Mascarenhas. 2002. 
Nutritional status in relation to the efficacy of the rhesus-human reassortant, 
tetravalent rotavirus vaccine (RRV-TV) in infants from Belem, para state, Brazil. 
Revista do Instituto de Medicina Tropical de Sao Paulo 44:13-16. 
90. Linhares, A. C., C. F. Lanata, W. P. Hausdorff, Y. B. Gabbay, and R. E. 
Black. 1999. Reappraisal of the Peruvian and Brazilian lower titer tetravalent 
rhesus-human reassortant rotavirus vaccine efficacy trials: analysis by severity of 
diarrhea. The Pediatric infectious disease journal 18:1001-1006. 
91. Longini, I. M., Jr., A. Nizam, M. Ali, M. Yunus, N. Shenvi, and J. D. 
Clemens. 2007. Controlling endemic cholera with oral vaccines. PLoS medicine 
4:e336. 
92. Lopez-Vidal, Y., J. J. Calva, A. Trujillo, A. Ponce de Leon, A. Ramos, A. M. 
Svennerholm, and G. M. Ruiz-Palacios. 1990. Enterotoxins and adhesins of 
enterotoxigenic Escherichia coli: are they risk factors for acute diarrhea in the 
community? The Journal of infectious diseases 162:442-447. 
93. Lopez, A. L., J. D. Clemens, J. Deen, and L. Jodar. 2008. Cholera vaccines for 
the developing world. Human vaccines 4:165-169. 
94. Lucas, M. E., J. L. Deen, L. von Seidlein, X. Y. Wang, J. Ampuero, M. Puri, 
M. Ali, M. Ansaruzzaman, J. Amos, A. Macuamule, P. Cavailler, P. J. 
Guerin, C. Mahoudeau, P. Kahozi-Sangwa, C. L. Chaignat, A. Barreto, F. F. 
Songane, and J. D. Clemens. 2005. Effectiveness of mass oral cholera 
vaccination in Beira, Mozambique. The New England journal of medicine 
352:757-767. 
95. Lundin, B. S., C. Johansson, and A. M. Svennerholm. 2002. Oral 
immunization with a Salmonella enterica serovar typhi vaccine induces specific 
circulating mucosa-homing CD4(+) and CD8(+) T cells in humans. Infection and 
immunity 70:5622-5627. 
96. Lycke, N., and J. Holmgren. 1986. Intestinal mucosal memory and presence of 
memory cells in lamina propria and Peyer's patches in mice 2 years after oral 
immunization with cholera toxin. Scandinavian journal of immunology 23:611-
616. 
97. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin 
on gut mucosal immune responses to orally presented antigens. Immunology 
59:301-308. 
98. Lycke, N., A. M. Svennerholm, and J. Holmgren. 1986. Strong biotype and 
serotype cross-protective antibacterial and antitoxic immunity in rabbits after 
cholera infection. Microbial pathogenesis 1:361-371. 
99. Mahalanabis, D., A. L. Lopez, D. Sur, J. Deen, B. Manna, S. Kanungo, L. von 
Seidlein, R. Carbis, S. H. Han, S. H. Shin, S. Attridge, R. Rao, J. Holmgren, 
J. Clemens, and S. K. Bhattacharya. 2008. A randomized, placebo-controlled 
trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children 
in a cholera endemic area in Kolkata, India. PLoS ONE 3:e2323. 
100. McKenzie, R., A. L. Bourgeois, F. Engstrom, E. Hall, H. S. Chang, J. G. 
Gomes, J. L. Kyle, F. Cassels, A. K. Turner, R. Randall, M. Darsley, C. Lee, 
P. Bedford, J. Shimko, and D. A. Sack. 2006. Comparative safety and 
  ‐ 70 ‐
immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine 
strains in healthy adults. Infection and immunity 74:994-1000. 
101. Meydani, A., T. Ahmed, and S. N. Meydani. 2005. Aging, nutritional status, 
and infection in the developing world. Nutrition reviews 63:233-246. 
102. Mollicone, R., J. Bara, J. Le Pendu, and R. Oriol. 1985. Immunohistologic 
pattern of type 1 (Lea, Leb) and type 2 (X, Y, H) blood group-related antigens in 
the human pyloric and duodenal mucosae. Laboratory investigation 53:219-227. 
103. Mollicone, R., I. Reguigne, R. J. Kelly, A. Fletcher, J. Watt, S. Chatfield, A. 
Aziz, H. S. Cameron, B. W. Weston, and J. B. Lowe. 1994. Molecular basis for 
Lewis alpha(1,3/1,4)-fucosyltransferase gene deficiency (FUT3) found in Lewis-
negative Indonesian pedigrees. Journal of biological chemistry 269:20987-20994. 
104. Morrow, A. L., and J. M. Rangel. 2004. Human milk protection against 
infectious diarrhea: implications for prevention and clinical care. Semin Pediatr 
Infect Dis 15:221-228. 
105. Morrow, A. L., G. M. Ruiz-Palacios, X. Jiang, and D. S. Newburg. 2005. 
Human-milk glycans that inhibit pathogen binding protect breast-feeding infants 
against infectious diarrhea. The Journal of nutrition 135:1304-1307. 
106. Mosley, W. H., K. M. Aziz, A. S. Rahman, A. K. Chowdhury, and A. Ahmed. 
1973. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural 
Bangladesh--three years of observation. Bulletin of the World Health 
Organization 49:381-387. 
107. Osendarp, S. J., H. Prabhakar, G. J. Fuchs, J. M. van Raaij, H. Mahmud, F. 
Tofail, M. Santosham, and R. E. Black. 2007. Immunization with the 
heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of 
zinc supplementation. Vaccine 25:3347-3354. 
108. Overbeck, S., L. Rink, and H. Haase. 2008. Modulating the immune response 
by oral zinc supplementation: a single approach for multiple diseases. Archivum 
immunologiae et therapiae experimentalis 56:15-30. 
109. Pasricha, S. 1983. Lewis antibodies in pregnant Indian, British & Pakistani 
women. The Indian journal of medical research 77:850-853. 
110. Perry, R. T., C. V. Plowe, B. Koumare, F. Bougoudogo, K. L. Kotloff, G. A. 
Losonsky, S. S. Wasserman, and M. M. Levine. 1998. A single dose of live oral 
cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and 
HIV-noninfected adults in Mali. Bulletin of the World Health Organization 
76:63-71. 
111. Pflug, W., G. Bassler, and B. Eberspacher. 1989. ABO and Lewis typing of 
secretion stains on nitrocellulose membranes using a new dot-blot-ELISA 
technique. Forensic science international 43:171-182. 
112. Prasad, A. S. 2008. Clinical, immunological, anti-inflammatory and antioxidant 
roles of zinc. Experimental gerontology 43:370-377. 
113. Prasad, A. S. 2008. Zinc in human health: effect of zinc on immune cells. 
Molecular medicine 14:353-357. 
114. Qadri, F., F. Ahmed, T. Ahmed, and A. M. Svennerholm. 2006. Homologous 
and cross-reactive immune responses to enterotoxigenic Escherichia coli 
colonization factors in Bangladeshi children. Infection and immunity 74:4512-
4518. 
  ‐ 71 ‐
115. Qadri, F., F. Ahmed, M. M. Karim, C. Wenneras, Y. A. Begum, M. Abdus 
Salam, M. J. Albert, and J. R. McGhee. 1999. Lipopolysaccharide- and cholera 
toxin-specific subclass distribution of B-cell responses in cholera. Clinical and 
diagnostic laboratory immunology 6:812-818. 
116. Qadri, F., T. Ahmed, F. Ahmed, Y. A. Begum, D. A. Sack, and A. M. 
Svennerholm. 2006. Reduced doses of oral killed enterotoxigenic Escherichia 
coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi 
infants 6-17 months of age: dosing studies in different age groups. Vaccine 
24:1726-1733. 
117. Qadri, F., T. Ahmed, F. Ahmed, R. Bradley Sack, D. A. Sack, and A. M. 
Svennerholm. 2003. Safety and immunogenicity of an oral, inactivated 
enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in 
Bangladeshi children 18-36 months of age. Vaccine 21:2394-2403. 
118. Qadri, F., T. Ahmed, M. A. Wahed, F. Ahmed, N. A. Bhuiyan, A. S. Rahman, 
J. D. Clemens, R. E. Black, and M. J. Albert. 2004. Suppressive effect of zinc 
on antibody response to cholera toxin in children given the killed, B subunit-
whole cell, oral cholera vaccine. Vaccine 22:416-421. 
119. Qadri, F., T. R. Bhuiyan, K. K. Dutta, R. Raqib, M. S. Alam, N. H. Alam, A. 
M. Svennerholm, and M. M. Mathan. 2004. Acute dehydrating disease caused 
by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and 
inflammatory mediators at the mucosal surface of the gut. Gut 53:62-69. 
120. Qadri, F., M. I. Chowdhury, S. M. Faruque, M. A. Salam, T. Ahmed, Y. A. 
Begum, A. Saha, A. Al Tarique, L. V. Seidlein, E. Park, K. P. Killeen, J. J. 
Mekalanos, J. D. Clemens, and D. A. Sack. 2007. Peru-15, a live attenuated oral 
cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. 
Vaccine 25:231-238. 
121. Qadri, F., M. I. Chowdhury, S. M. Faruque, M. A. Salam, T. Ahmed, Y. A. 
Begum, A. Saha, M. S. Alam, K. Zaman, L. V. Seidlein, E. Park, K. P. 
Killeen, J. J. Mekalanos, J. D. Clemens, and D. A. Sack. 2005. Randomized, 
controlled study of the safety and immunogenicity of Peru-15, a live attenuated 
oral vaccine candidate for cholera, in adult volunteers in Bangladesh. The Journal 
of infectious diseases 192:573-579. 
122. Qadri, F., S. K. Das, A. S. Faruque, G. J. Fuchs, M. J. Albert, R. B. Sack, and 
A. M. Svennerholm. 2000. Prevalence of toxin types and colonization factors in 
enterotoxigenic Escherichia coli isolated during a 2-year period from diarrheal 
patients in Bangladesh. Journal of clinical microbiology 38:27-31. 
123. Qadri, F., G. Jonson, Y. A. Begum, C. Wenneras, M. J. Albert, M. A. Salam, 
and A. M. Svennerholm. 1997. Immune response to the mannose-sensitive 
hemagglutinin in patients with cholera due to Vibrio cholerae O1 and O0139. 
Clinical and diagnostic laboratory immunology 4:429-434. 
124. Qadri, F., A. I. Khan, A. S. Faruque, Y. A. Begum, F. Chowdhury, G. B. 
Nair, M. A. Salam, D. A. Sack, and A. M. Svennerholm. 2005. Enterotoxigenic 
Escherichia coli and Vibrio cholerae diarrhea, Bangladesh, 2004. Emerging 
infectious diseases 11:1104-1107. 
125. Qadri, F., G. Mohi, J. Hossain, T. Azim, A. M. Khan, M. A. Salam, R. B. 
Sack, M. J. Albert, and A. M. Svennerholm. 1995. Comparison of the 
  ‐ 72 ‐
vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with 
the response in cholera due to Vibrio cholerae O1. Clinical and diagnostic 
laboratory immunology 2:685-688. 
126. Qadri, F., E. T. Ryan, A. S. Faruque, F. Ahmed, A. I. Khan, M. M. Islam, S. 
M. Akramuzzaman, D. A. Sack, and S. B. Calderwood. 2003. Antigen-specific 
immunoglobulin A antibodies secreted from circulating B cells are an effective 
marker for recent local immune responses in patients with cholera: comparison to 
antibody-secreting cell responses and other immunological markers. Infection and 
immunity 71:4808-4814. 
127. Qadri, F., A. Saha, T. Ahmed, A. Al Tarique, Y. A. Begum, and A. M. 
Svennerholm. 2007. Disease burden due to enterotoxigenic Escherichia coli in 
the first 2 years of life in an urban community in Bangladesh. Infection and 
immunity 75:3961-3968. 
128. Qadri, F., A. M. Svennerholm, A. S. Faruque, and R. B. Sack. 2005. 
Enterotoxigenic Escherichia coli in developing countries: epidemiology, 
microbiology, clinical features, treatment, and prevention. Clinical microbiology 
reviews 18:465-483. 
129. Qadri, F., C. Wenneras, F. Ahmed, M. Asaduzzaman, D. Saha, M. J. Albert, 
R. B. Sack, and A. Svennerholm. 2000. Safety and immunogenicity of an oral, 
inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine 
in Bangladeshi adults and children. Vaccine 18:2704-2712. 
130. Quiding, M., I. Nordstrom, A. Kilander, G. Andersson, L. A. Hanson, J. 
Holmgren, and C. Czerkinsky. 1991. Intestinal immune responses in humans. 
Oral cholera vaccination induces strong intestinal antibody responses and 
interferon-gamma production and evokes local immunological memory. The 
Journal of clinical investigation 88:143-148. 
131. Rao, M. R., T. F. Wierzba, S. J. Savarino, R. Abu-Elyazeed, N. El-Ghoreb, E. 
R. Hall, A. Naficy, I. Abdel-Messih, R. W. Frenck, Jr., A. M. Svennerholm, 
and J. D. Clemens. 2005. Serologic correlates of protection against 
enterotoxigenic Escherichia coli diarrhea. The Journal of infectious diseases 
191:562-570. 
132. Rennels, M. B. 1996. Influence of breast-feeding and oral poliovirus vaccine on 
the immunogenicity and efficacy of rotavirus vaccines. The Journal of infectious 
diseases 174 Suppl 1:S107-111. 
133. Richie, E. E., N. H. Punjabi, Y. Y. Sidharta, K. K. Peetosutan, M. M. 
Sukandar, S. S. Wasserman, M. M. Lesmana, F. F. Wangsasaputra, S. S. 
Pandam, M. M. Levine, P. P. O'Hanley, S. J. Cryz, and C. H. Simanjuntak. 
2000. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in 
North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18:2399-2410. 
134. Rink, L., and H. Haase. 2007. Zinc homeostasis and immunity. Trends in 
immunology 28:1-4. 
135. Rockabrand, D. M., H. I. Shaheen, S. B. Khalil, L. F. Peruski, Jr., P. J. 
Rozmajzl, S. J. Savarino, M. R. Monteville, R. W. Frenck, A. M. 
Svennerholm, S. D. Putnam, and J. W. Sanders. 2006. Enterotoxigenic 
Escherichia coli colonization factor types collected from 1997 to 2001 in US 
  ‐ 73 ‐
military personnel during operation Bright Star in northern Egypt. Diagnostic 
microbiology and infectious disease. 
136. Rudin, A., M. M. McConnell, and A. M. Svennerholm. 1994. Monoclonal 
antibodies against enterotoxigenic Escherichia coli colonization factor antigen I 
(CFA/I) that cross-react immunologically with heterologous CFAs. Infection and 
immunity 62:4339-4346. 
137. Ruiz-Palacios, G. M., L. E. Cervantes, P. Ramos, B. Chavez-Munguia, and D. 
S. Newburg. 2003. Campylobacter jejuni binds intestinal H(O) antigen (Fuc 
alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk 
inhibit its binding and infection. Journal of biological chemistry 278:14112-
14120. 
138. Sack, D., Qadri, F., Svennerholm, A.M. 2008. Determinants of responses to oral 
vaccines in developing countries, p. 71-79. In O. Hernell (ed.), Annales Nestle, 
vol. 66. Karger, Umea. 
139. Sack, D. A., J. Shimko, O. Torres, A. L. Bourgeois, D. S. Francia, B. 
Gustafsson, A. Karnell, I. Nyquist, and A. M. Svennerholm. 2007. 
Randomised, double-blind, safety and efficacy of a killed oral vaccine for 
enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 
25:4392-4400. 
140. Sanchez, J., and J. Holmgren. 1989. Recombinant system for overexpression of 
cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development. 
Proceedings of the National Academy of Sciences of the United States of America 
86:481-485. 
141. Sanchez, J., and J. Holmgren. 2005. Virulence factors, pathogenesis and 
vaccine protection in cholera and ETEC diarrhea. Current opinion in immunology 
17:388-398. 
142. Saunders, J. 2004. Vesicles in virulence. Nature reviews 2:86-87. 
143. Savarino, S. J., F. M. Brown, E. Hall, S. Bassily, F. Youssef, T. Wierzba, L. 
Peruski, N. A. El-Masry, M. Safwat, M. Rao, M. Jertborn, A. M. 
Svennerholm, Y. J. Lee, and J. D. Clemens. 1998. Safety and immunogenicity 
of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine 
in Egyptian adults. The Journal of infectious diseases 177:796-799. 
144. Savarino, S. J., E. R. Hall, S. Bassily, F. M. Brown, F. Youssef, T. F. 
Wierzba, L. Peruski, N. A. El-Masry, M. Safwat, M. Rao, H. El Mohamady, 
R. Abu-Elyazeed, A. Naficy, A. M. Svennerholm, M. Jertborn, Y. J. Lee, and 
J. D. Clemens. 1999. Oral, inactivated, whole cell enterotoxigenic Escherichia 
coli plus cholera toxin B subunit vaccine: results of the initial evaluation in 
children. PRIDE Study Group. The Journal of infectious diseases 179:107-114. 
145. Savarino, S. J., E. R. Hall, S. Bassily, T. F. Wierzba, F. G. Youssef, L. F. 
Peruski, Jr., R. Abu-Elyazeed, M. Rao, W. M. Francis, H. El Mohamady, M. 
Safwat, A. B. Naficy, A. M. Svennerholm, M. Jertborn, Y. J. Lee, and J. D. 
Clemens. 2002. Introductory evaluation of an oral, killed whole cell 
enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian 
infants. The Pediatric infectious disease journal 21:322-330. 
146. Shaheen, H. I., I. A. Abdel Messih, J. D. Klena, A. Mansour, Z. El-Wakkeel, 
T. F. Wierzba, J. W. Sanders, S. B. Khalil, D. M. Rockabrand, M. R. 
  ‐ 74 ‐
Monteville, P. J. Rozmajzl, A. M. Svennerholm, and R. W. Frenck. 2009. 
Phenotypic and genotypic analysis of enterotoxigenic Escherichia coli in samples 
obtained from Egyptian children presenting to referral hospitals. Journal of 
clinical microbiology 47:189-197. 
147. Shamsuzzaman, S., T. Ahmed, K. Mannoor, Y. A. Begum, P. K. Bardhan, R. 
B. Sack, D. A. Sack, A. M. Svennerholm, J. Holmgren, and F. Qadri. 2009. 
Robust gut associated vaccine-specific antibody-secreting cell responses are 
detected at the mucosal surface of Bangladeshi subjects after immunization with 
an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: 
Comparison with other mucosal and systemic responses. Vaccine 27:1386-1392. 
148. Sharma, N. C., P. K. Mandal, R. Dhillon, and M. Jain. 2007. Changing profile 
of Vibrio cholerae O1, O139 in Delhi & its periphery (2003-2005). Indian journal 
of medical research 125:633-640. 
149. Simanjuntak, C. H., P. O'Hanley, N. H. Punjabi, F. Noriega, G. Pazzaglia, P. 
Dykstra, B. Kay, Suharyono, A. Budiarso, A. R. Rifai, and et al. 1993. Safety, 
immunogenicity, and transmissibility of single-dose live oral cholera vaccine 
strain CVD 103-HgR in 24- to 59-month-old Indonesian children. The Journal of 
infectious diseases 168:1169-1176. 
150. Simanjuntak, C. H., F. P. Paleologo, N. H. Punjabi, R. Darmowigoto, 
Soeprawoto, H. Totosudirjo, P. Haryanto, E. Suprijanto, N. D. Witham, and 
S. L. Hoffman. 1991. Oral immunisation against typhoid fever in Indonesia with 
Ty21a vaccine. Lancet 338:1055-1059. 
151. Sjoling, A., G. Wiklund, S. J. Savarino, D. I. Cohen, and A. M. Svennerholm. 
2007. Comparative analyses of phenotypic and genotypic methods for detection 
of enterotoxigenic Escherichia coli toxins and colonization factors. Journal of 
clinical microbiology 45:3295-3301. 
152. Suharyono, C. Simanjuntak, N. Witham, N. Punjabi, D. G. Heppner, G. 
Losonsky, H. Totosudirjo, A. R. Rifai, J. Clemens, Y. L. Lim, and et al. 1992. 
Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-
HgR in 5-9-year-old Indonesian children. Lancet 340:689-694. 
153. Sur, D., J. L. Deen, B. Manna, S. K. Niyogi, A. K. Deb, S. Kanungo, B. L. 
Sarkar, D. R. Kim, M. C. Danovaro-Holliday, K. Holliday, V. K. Gupta, M. 
Ali, L. von Seidlein, J. D. Clemens, and S. K. Bhattacharya. 2005. The burden 
of cholera in the slums of Kolkata, India: data from a prospective, community 
based study. Arch Dis Child 90:1175-1181. 
154. Svahn, A., A. Linde, R. Thorstensson, K. Karlen, L. Andersson, and H. 
Gaines. 2003. Development and evaluation of a flow-cytometric assay of specific 
cell-mediated immune response in activated whole blood for the detection of cell-
mediated immunity against varicella-zoster virus. Journal of immunological 
methods 277:17-25. 
155. Svennerholm, A. M., L. Gothefors, D. A. Sack, P. K. Bardhan, and J. 
Holmgren. 1984. Local and systemic antibody responses and immunological 
memory in humans after immunization with cholera B subunit by different routes. 
Bulletin of the World Health Organization 62:909-918. 
  ‐ 75 ‐
156. Svennerholm, A. M., and J. Holmgren. 1995. Oral vaccines against cholera and 
enterotoxigenic Escherichia coli diarrhea. Advances in experimental medicine and 
biology 371B:1623-1628. 
157. Svennerholm, A. M., J. Holmgren, and D. A. Sack. 1989. Development of oral 
vaccines against enterotoxinogenic Escherichia coli diarrhoea. Vaccine 7:196-
198. 
158. Svennerholm, A. M., M. Jertborn, L. Gothefors, A. M. Karim, D. A. Sack, 
and J. Holmgren. 1984. Mucosal antitoxic and antibacterial immunity after 
cholera disease and after immunization with a combined B subunit-whole cell 
vaccine. J Infect Dis 149:884-893. 
159. Svennerholm, A. M., and D. Steele. 2004. Microbial-gut interactions in health 
and disease. Progress in enteric vaccine development. Best practice & research 
18:421-445. 
160. Svennerholm, A. M., Svarino, S. 2004. Oral inactivated whole cell B subunit 
combination vaccine against enterotoxigenic Escherichia coli, p. 737. New 
Generation Vaccine. Marcel Decker, Inc, New York. 
161. Svennerholm, A. M., and J. Tobias. 2008. Vaccines against enterotoxigenic 
Escherichia coli. Expert Rev Vaccines 7:795-804. 
162. Svennerholm, A. M., C. Wenneras, J. Holmgren, M. M. McConnell, and B. 
Rowe. 1990. Roles of different coli surface antigens of colonization factor antigen 
II in colonization by and protective immunogenicity of enterotoxigenic 
Escherichia coli in rabbits. Infection and immunity 58:341-346. 
163. Tacket, C. O., K. L. Kotloff, G. Losonsky, J. P. Nataro, J. Michalski, J. B. 
Kaper, R. Edelman, and M. M. Levine. 1997. Volunteer studies investigating 
the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 
111. American journal of tropical medicine and hygiene 56:533-537. 
164. Tacket, C. O., G. Losonsky, S. Livio, R. Edelman, J. Crabb, and D. 
Freedman. 1999. Lack of prophylactic efficacy of an enteric-coated bovine 
hyperimmune milk product against enterotoxigenic Escherichia coli challenge 
administered during a standard meal. J Infect Dis 180:2056-2059. 
165. Tacket, C. O., R. K. Taylor, G. Losonsky, Y. Lim, J. P. Nataro, J. B. Kaper, 
and M. M. Levine. 1998. Investigation of the roles of toxin-coregulated pili and 
mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 
infection. Infection and immunity 66:692-695. 
166. Taylor, D. N., K. P. Killeen, D. C. Hack, J. R. Kenner, T. S. Coster, D. T. 
Beattie, J. Ezzell, T. Hyman, A. Trofa, M. H. Sjogren, and et al. 1994. 
Development of a live, oral, attenuated vaccine against El Tor cholera. The 
Journal of infectious diseases 170:1518-1523. 
167. Taylor, D. N., J. L. Sanchez, J. M. Castro, C. Lebron, C. M. Parrado, D. E. 
Johnson, C. O. Tacket, G. A. Losonsky, S. S. Wasserman, M. M. Levine, and 
S. J. Cryz. 1999. Expanded safety and immunogenicity of a bivalent, oral, 
attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States 
military personnel stationed in Panama. Infection and immunity 67:2030-2034. 
168. Thiem, V. D., J. L. Deen, L. von Seidlein, G. Canh do, D. D. Anh, J. K. Park, 
M. Ali, M. C. Danovaro-Holliday, N. D. Son, N. T. Hoa, J. Holmgren, and J. 
  ‐ 76 ‐
D. Clemens. 2006. Long-term effectiveness against cholera of oral killed whole-
cell vaccine produced in Vietnam. Vaccine 24:4297-4303. 
169. Tobias, J., M. Lebens, I. Bolin, G. Wiklund, and A. M. Svennerholm. 2008. 
Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing 
high and immunogenic levels of enterotoxigenic E. coli colonization factor I 
fimbriae. Vaccine 26:743-752. 
170. Tobias, J., M. Lebens, S. Kallgard, M. Nicklasson, and A. M. Svennerholm. 
2008. Role of different genes in the CS6 operon for surface expression of 
Enterotoxigenic Escherichia coli colonization factor CS6. Vaccine 26:5373-5380. 
171. Trach, D. D., P. D. Cam, N. T. Ke, M. R. Rao, D. Dinh, P. V. Hang, N. V. 
Hung, D. G. Canh, V. D. Thiem, A. Naficy, B. Ivanoff, A. M. Svennerholm, J. 
Holmgren, and J. D. Clemens. 2002. Investigations into the safety and 
immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bulletin 
of the World Health Organization 80:2-8. 
172. Turner, A. K., J. C. Beavis, J. C. Stephens, J. Greenwood, C. Gewert, N. 
Thomas, A. Deary, G. Casula, A. Daley, P. Kelly, R. Randall, and M. J. 
Darsley. 2006. Construction and phase I clinical evaluation of the safety and 
immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain 
expressing colonization factor antigen CFA/I. Infection and immunity 74:1062-
1071. 
173. Turner, A. K., T. D. Terry, D. A. Sack, P. Londono-Arcila, and M. J. 
Darsley. 2001. Construction and characterization of genetically defined aro omp 
mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and 
immunogenicity in humans. Infection and immunity 69:4969-4979. 
174. Upham, J. W., A. Rate, J. Rowe, M. Kusel, P. D. Sly, and P. G. Holt. 2006. 
Dendritic cell immaturity during infancy restricts the capacity to express vaccine-
specific T-cell memory. Infection and immunity 74:1106-1112. 
175. van Loon, F. P., J. D. Clemens, D. A. Sack, M. R. Rao, F. Ahmed, S. 
Chowdhury, J. R. Harris, M. Ali, J. Chakraborty, M. R. Khan, and et al. 
1991. ABO blood groups and the risk of diarrhea due to enterotoxigenic 
Escherichia coli. The Journal of infectious diseases 163:1243-1246. 
176. VanDerslice, J., B. Popkin, and J. Briscoe. 1994. Drinking-water quality, 
sanitation, and breast-feeding: their interactive effects on infant health. Bulletin of 
the World Health Organization 72:589-601. 
177. Voss, E., P. A. Manning, and S. R. Attridge. 1996. The toxin-coregulated pilus 
is a colonization factor and protective antigen of Vibrio cholerae El Tor. 
Microbial pathogenesis 20:141-153. 
178. Walker, R. I. 2005. Considerations for development of whole cell bacterial 
vaccines to prevent diarrheal diseases in children in developing countries. 
Vaccine 23:3369-3385. 
179. Walker, R. I. 2005. New vaccines against enteric bacteria for children in less 
developed countries. Expert review of vaccines 4:807-812. 
180. Walker, R. I., D. Steele, and T. Aguado. 2007. Analysis of strategies to 
successfully vaccinate infants in developing countries against enterotoxigenic E. 
coli (ETEC) disease. Vaccine 25:2545-2566. 
  ‐ 77 ‐
181. Walker, R. I., L. L. Van De Verg, R. H. Hall, C. K. Schmitt, K. Woo, and V. 
Hale. 2005. Enteric vaccines for pediatric use. Workshop summary. Vaccine 
23:5432-5439. 
182. Watkins, W. M. 1980. Biochemistry and Genetics of the ABO, Lewis, and P 
blood group systems. Advances in human genetics 10:1-136, 379-185. 
183. Wellinghausen, N., H. Kirchner, and L. Rink. 1997. The immunobiology of 
zinc. Immunology today 18:519-521. 
184. Wenneras, C., and V. Erling. 2004. Prevalence of enterotoxigenic Escherichia 
coli-associated diarrhoea and carrier state in the developing world. Journal of 
health, population, and nutrition 22:370-382. 
185. Wenneras, C., F. Qadri, P. K. Bardhan, R. B. Sack, and A. M. Svennerholm. 
1999. Intestinal immune responses in patients infected with enterotoxigenic 
Escherichia coli and in vaccinees. Infection and immunity 67:6234-6241. 
186. WHO. 1987. Programme for control of diarrhoeal diseases (CDD/93.3 Rev. 1), p. 
9–20. In Manual for laboratory investigations of acute enteric infections. World 
Health Organization, Geneva, Switzerland. 
187. Wolf, M. K. 1997. Occurrence, distribution, and associations of O and H 
serogroups, colonization factor antigens, and toxins of enterotoxigenic 
Escherichia coli. Clinical microbiology reviews 10:569-584. 
188. Wolf, M. K., D. N. Taylor, E. C. Boedeker, K. C. Hyams, D. R. Maneval, M. 
M. Levine, K. Tamura, R. A. Wilson, and P. Echeverria. 1993. 
Characterization of enterotoxigenic Escherichia coli isolated from U.S. troops 
deployed to the Middle East. Journal of clinical microbiology 31:851-856. 
189. Yu, J., F. Cassels, T. Scharton-Kersten, S. A. Hammond, A. Hartman, E. 
Angov, B. Corthesy, C. Alving, and G. Glenn. 2002. Transcutaneous 
immunization using colonization factor and heat-labile enterotoxin induces 
correlates of protective immunity for enterotoxigenic Escherichia coli. Infection 
and immunity 70:1056-1068. 
190. Zinkernagel, R. M., and H. Hengartner. 2001. Regulation of the immune 
response by antigen. Science 293:251-253. 
 
 
 
 
 
 
 
 
 
 
